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The Peterson laboratory has had a long-standing interest in fluorescent 
probes of biological systems. My research in the Peterson group has focused on 
the design, synthesis, and biological evaluation of fluorescent small molecules 
that exhibit specific patterns of subcellular localization and studies of their 
downstream biological effects. The relationship between this approach and the 
strategy of phenotypic drug discovery is described in Chapter 1. Chapter 2 
describes the discovery of the intrinsic blue fluorescence of the potent anti-
cancer/anti-viral compound AKT inhibitor-IV (AKTIV), and how we used this 
property to discover that its mechanism of biological action involves accumulation 
in mitochondria and associated effects on mitochondrial morphology and cellular 
bioenergetics. Chapter 3 describes the synthesis of a novel class of hydrophobic 
fluorinated rhodol fluorophores that selectively accumulate in the endoplasmic 
reticulum. These fluorophores were shown to enable delivery of linked small-
molecules to control a specific biological pathway in this organelle. Building on 
these studies, Chapter 4 describes screening of a variety of fluorescent probes 
against the vertebrate model organism zebrafish (Danio rerio). These studies led 
to the discoveries that hydrophobic rhodamines can be used to target zebrafish 
mitochondria, and acid-activated fluorophores can accumulate in acidic tissues of 
the embryonic yolk. Chapter 5 describes another project involving the synthesis 
of novel cholesteryl dimers and analysis of the in vitro stability of liposomes that 
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Phenotypic Drug Discovery and Subcellular Targeting of Small Molecules 
 
1.1 Phenotypic Approaches for Discovery of Novel Mechanisms 
 Most first-in-class drugs are discovered through a process termed 
phenotypic screening.1-2 These agents exhibit novel mechanisms of action and 
are crucial for tackling neglected diseases or diseases with suboptimal therapies. 
This screening approach uses models of disease in cell culture or in vivo to 
identify candidate therapeutics without specifying a molecular target (Figure 1.1, 
compare panels A and B). Between 1999 and 2008, 28 out of 50 approved small-
molecule therapies with new mechanisms of action were derived from some type 
of phenotypic screen (Figure 1.1, panel C).1 The remaining small-molecule 
agents were derived from a target-based approach, exemplified by screening and 
optimizing a small-molecule inhibitor against an expressed protein target in vitro, 
typically based on structural data. This target-based approach is the principal tool 
used to identify “follower” drugs, where second- or third-generation molecules 
share a mechanism of action with first-in-class agents after a target has been 
clinically validated. The heavy reliance of the pharmaceutical industry on 
screening of large chemical libraries, and an infrastructure based on target-based 
screening and optimization, is being challenged, as it has been suggested the 
investment in this approach has not significantly increased the number of agents 
brought to market. Although the distinction between phenotypic and target-based 
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discoveries can be controversial due to modern approaches that combine both 
techniques,2 it is clear that phenotypic screening plays an important role in the 
development of novel therapies in the modern drug discovery process. 
 
Figure 1.1. General workflows of target-based (Panel A) and phenotype-based 
(Panel B) drug discovery. New therapies approved by the FDA, organized by 
generation, type, and origin of discovery, are shown in Panel C. 
 
 The power of phenotypic discovery is attributed to a number of factors. 
First, this approach, unbiased by interest in a specific target protein, does not 
presume a cause-and-effect relationship between a specific target and 
downstream modulation of the disease, which can lead to serendipitous 
discoveries.3 Second, successful cell-based and in vivo screening methods 
requires certain favorable bio-pharmacokinetic properties such as permeability, 
tissue accumulation, and metabolism in order for compounds to be active. In 
contrast, the pharmacokinetics of candidates optimized in vitro in a target-based 
screen typically must be optimized after screening.  
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Phenotypic screening in earlier eras of pharmaceutical development relied 
heavily on direct experimentation in mammals such as mice or rats. Considering 
the significant cost of doing modern animal-based screens on large scales, 
phenotypic assays today may involve cell-based models, invertebrate animals, 
and small vertebrate model organisms. Modern genetic techniques, such as 
CRISPR/Cas9 genome editing,4 allow easier entry into novel models for this 
approach. Advances in high-throughput cellular and in vivo screening techniques 
allow more quantitative approaches based on microscopy5 and flow cytometry.6 
High-content phenotypic assays can be used for high-throughput screening of 
small-molecule libraries.7 
 
1.2 Fluorescent Probes in Phenotypic Screens 
 Fluorescent assays have played a large role in phenotypic screens 
because fluorescence can often be bright, easily visualized, and readily 
quantified in biological systems.8 Both fluorescent transgenes and small-
molecule probes have been used in phenotypic assays, and often both 
approaches compliment each other in multicolor experiments. The former 
typically involves the expression of fluorescent proteins, such as green-
fluorescent protein (GFP), and following changes in expression, distribution, or 
lifetime. For example, a phenotypic screen looking for changes in the cellular 
distribution of the protein FOXO1 was originally used to discover AKT Inhibitor-
IV, the small-molecule that is central to Chapter 2 of this dissertation.9 Other 
examples include siRNA screens for genes affecting trafficking of the mannose-
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6-phosphate receptor, as it relates to neurodegenerative diseases,10 and small-
molecule screens against ER-mitochondrial trafficking and morphology related to 
models of Parkinson’s disease.11  
Compared with fluorescent proteins, fluorescent small molecules have 
been less frequently used in phenotypic screens. This is likely due to the greater 
complexity involved in creation of a chemical probe verses a genetic construct for 
most biologists. However, small-molecule fluorophores have great potential for 
novel phenotypic screens because of their diverse chemical, structural, and 
photophysical properties. For example, small-molecule fluorescent probes have 
been used in phenotypic screens for vacuolization in the malarial parasite P. 
falciparum,12 protection of the mitochondrial network critical in 
neurodegeneration,13 and cytotoxicity in the blood fluke Schistosoma.14 One 
interesting example of using small-molecule fluorophores in a phenotypic assay 
incorporated five different fluorescent organelle markers with unique spectral 
profiles to simultaneously probe the distribution and morphology of the nucleus, 
the mitochondria, the endoplasmic reticulum, the Golgi apparatus, and the actin 
network.15 A major focus of this dissertation is studies of the biological properties 
of fluorescent probes, discovered by phenotypic screening, that accumulate in 




Figure 1.2. Common organelles of mammalian cells and mechanisms for 
targeting of these subcellular compartments with small molecules.  
 
1.3. Targeting Subcellular Compartments with Small Molecules 
Mammalian cells are a highly complex biological system. This system is 
compartmentalized into various cellular organelles that include specific subsets 
of biomolecules (Figure 1.2). The cell maintains this non-uniform distribution of 
biomolecules through complex sorting systems. Proteins that are targeted to 
subcellular organelles or subdomains of organelles include peptide sequences 
encoding a cellular “address.” For example, proteins destined for localization in 
the endoplasmic reticulum (ER) include the tetrapeptide sequence KDEL at the 
C-terminus.16-18 This KDEL peptide signals for retrograde transport from the Golgi 
or cytosol back to the ER via specific receptors (KDEL1-3).18 Phospholipids, 
primarily synthesized in the ER and mitochondria, are similarly asymmetrically 
distributed in different subcellular membranes.19-20 This asymmetry is maintained 
by a system of protein transporters and controlled fusion of membrane vesicles.21  
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Since drug targets are non-uniformly distributed throughout the cell, 
effective pharmacological agents must be able to reach the intended target, while 
avoiding accumulation in non-relevant organelles.22-23 As previously mentioned, 
target-based drug discovery typically yields candidates that must be further 
optimized for pharmacokinetic properties. In order to make more “drug-like” 
molecules, this optimization may involves calculated and measured parameters 
such as lipid partitioning coefficients, hydrogen bond donors and acceptors, oral 
availability, and tissue distribution. However, for small molecules that affect 
intracellular targets, subcellular distribution represents an additional potentially 
important factor that has not been traditionally considered during drug 
development.  
The targeting of bioactive compounds to specific subcellular 
compartments is typically achieved by one of two mechanisms. First, small-
molecules can specifically accumulate in a subcellular compartment due to 
intrinsic physicochemical properties. Alternatively, subcellular delivery can result 
from interaction with an organelle-specific resident protein or linkage to a 
targeting signal. Fluorescent probes that accumulate in specific organelles allow 
investigation of mechanisms of subcellular targeting because their specific 
accumulation can be easily observed by fluorescence microscopy (see structures 
in Figures 1.3 and 1.5). In the following sections, the concept of subcellular 
targeting will be further defined by examples of small-molecules that accumulate 
in cellular compartments due to interaction with proteins, lipids, or unique 
physicochemical properties of an organelle. 
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1.3.1 The Plasma Membrane 
The plasma membrane, a lipid bilayer that separates the extracellular 
space from the cytosol, houses a variety different drug targets. These drug 
targets include major families of proteins such as the G-protein coupled receptors 
(GPCRs), receptor tyrosine kinases, viral fusion proteins, and ion channels. 
Drugs that reach the systemic circulation typically have free access to targets on 
the extracellular side of the plasma membrane. However, membrane anchoring 
by membrane integral peptides or lipids has been shown to be an effective tool in 
limiting the scope of the drug to the plasma membrane to enhance efficacy.24  
Enfuvirtide (T-20/Fuzeon)25 is a first-in-class viral fusion inhibitor used to 
treat infection by multi-drug resistant HIV. This drug is a synthetic 36-amino acid 
peptide the mimics the gp41 viral protein and prevents fusion of the virus with the 
plasma membrane of the host. When enfuvirtide was expressed fused to a 
membrane-spanning domain of the low-affinity nerve growth factor receptor 
(LNGFP), its potency against entry of HIV-1 was improved 20-fold compared with 
the non-anchored drug.26 Another peptide fusion inhibitor termed C34, based on 
a different portion of the pg41 sequence, was shown27 to also be a potent 
inhibitor of HIV-1 fusion (IC50 = 205 pM) and a membrane-targeted cholesterol-
linked analogue was shown to improve potency by over 50-fold (IC50 = 4 pM). 
The cholesterol-linked C34 also proved to be effective against enfuvirtide-
resistant viral strains.27 These examples of plasma membrane anchoring of 
fusion inhibitors illustrates potential advantages of localizing drugs to the same 
cellular compartment as their molecular target by controlling non-productive 
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diffusion. The cholesterol-linked C34 has been showed to preferentially associate 
with lipid rafts on the plasma membrane, exemplifying the value of domain-
specific targeting for small-molecule drugs within an organelle.28 The benefit of 
subcellular targeting by plasma membrane anchoring has also been 
demonstrated in a variety of other drug classes including hepatitis B viral fusion 
inhibitors,29 β-secretase inhibitors,30 and a class of lipidated GPCR modulators 
termed Pepducins.31  
As the first lipid membrane encountered by an agent, the plasma 
membrane can accumulate highly lipophilic molecules such as the long chain 
carbocyanine dye DiI (Figure 1.3 panel A).32 Fluorescent probes, such as DiI, 
targeted to the plasma membrane can be useful for studies of subcellular 
localization of agents by fluorescence microscopy. Because dyes of this category 
stably incorporate into the plasma membrane, they are also commonly used to 






Figure 1.3. Structures of molecular probes localized to specific subcellular 
regions. Panel A: The plasma-membrane anchored fluorophore DiI. Panel B: The 
lysosomotropic agents LysoTracker Red DNR-99 (Life Technologies), 
chloroquine, and the anticancer agent daunorubicin. Cholesterylamines with this 
general structure are typically localized to the plasma membrane and early 
endosomes. Panel C: Nuclear-localized compounds include the DNA minor-
groove binders Hoechst 33342 and DAPI, and the acridine mutagen ICR-191 
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1.3.2 Endosomes and Lysosomes 
The endosomal/lysosomal system, associated with the plasma membrane 
by dynamic membrane trafficking processes, is a series of membrane-enclosed 
compartments responsible for endocytosis, receptor trafficking, and digestion of 
nutrients. Endocytosis encompasses a number of mechanisms, including 
pinocytosis and receptor-mediated endocytosis (RME), where a cell internalizes 
extracellular material by invagination of the plasma membrane to generate 
vesicles that fuse to form endosomes that subsequently mature and fuse with 
lysosomes. The transition from early endosomes to late endosomes (pH ~6) and 
lysosomes (pH ~5) is accompanied by lowering of the luminal pH due to the 
protein vacuolar ATPase (V-ATPase).34 Interestingly, it has been shown that 
cancer cells typically exhibit elevated endosomal pH compared with normal 
cells.35-38 However, resistance to the anticancer drug Adriamycin in MCF-7 cells 
was shown to correlate with a decrease in endosomal pH, resulting in extensive 
endosomal trapping of the drug and, thereby, a decreased free concentration.35 A 
fluorescent probe that visualizes the ex vivo acidity caused by V-ATPase is 
discussed in Chapter 4 of this dissertation. Due to the relatively low pH of these 
compartments compared with the cytosol, weakly basic molecules such as the 
BODIPY fluorophore LysoTracker Red (pKa = 7.5, Life Technologies, Figure 1.3 
panel B) can selectively accumulate in the lumen of these organelles.39-41!This 
phenomena of lysosomal accumulation is termed lysosomotropism and is a 
common feature of moderately basic compounds (pKa ~ 7-9).41 The antimalarial 
drug chloroquine (pKa = 8.5, Figure 1.3 panel B) is known to accumulate in 
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lysosomes and is used in in vitro experiments to raise lysosomal lumen pH.39 The 
topoisomerase inhibitor daunorubicin is also lysosomotropic (pKa = 7.5, Figure 
1.3 panel B),42 and an increase in lysosomal trapping of daunorubicin coupled 
due to a decrease in the pH of the lumen of the lysosome has been implicated in 
clinical drug resistance.43 
Antibody-drug conjugates (ADCs) are a clinically successful class of drugs 
useful for targeting of cancer cells that overexpress distinctive cell-surface 
receptors.44-45 The antibody-receptor complex undergoes RME and enters 
endosomes and/or lysosomes. A linked cytotoxic warhead can then be released 
in these acidic compartments from an acid-labile linker such as a hydrazone, 
proteolytic cleavage of a linker, or complete degradation of the targeted antibody. 
Trastuzumab emtansine (marketed as Kadcyla), used to treat HER2-positive 
breast cancer, is composed of a monoclonal antibody that binds the receptor 
HER2 linked to the tubulin-binding agent maytansine.46-47 Upon RME, the 
antibody-receptor complex cycles through endosomal compartments, and the 
antibody is eventually degraded in the lysosome, which releases the potent 
cytotoxic agent maytansine. Brentuximab vedotin48-50 (marketed as Adcetris), a 
antibody against CD30 linked to the tubulin binding agent monomethyl auristatin 
E (MMAE), is used clinically to treat several types of lymphoma. In lysosomes, 
MMAE is liberated from the antibody by the protease capthesin B.49, 51 An 
increasing pipeline of ADCs44, 52 highlights the utility of targeted-release of potent 
cytotoxins in the endosomal/lysosomal system after RME. 
 12 
The Peterson laboratory has extensively studied mimics of cell surface 
receptors based on analogues of cholesterol. Probes derived from 
cholesterylamine (Figure 1.3, panel B)53 have been shown to rapidly cycle 
(recycling half-life ~3 min in Jurkat lymphocytes) between the plasma membrane 
and early endosomes, similar to the kinetics of trafficking of cell surface receptors 
during RME Examples of using these synthetic cholesterylamines to deliver 
covalent or non-covalent cargo to the endosomal/lysosomal system include 
fluorescent small-molecules,54-55 IgG,56 vancomycin,57 and membrane-lytic 
peptides.58 The precise mechanism of how these cholesterylamines incorporate 
into membranes, an active area of investigation by the Peterson laboratory, 
appears to involve a receptor-mediated process.59 These synthetic mimics of 
cell-surface receptors provide a unique tool for targeting of cargo to the lumen of 
endosomes. 
 
1.3.3 The Endoplasmic Reticulum 
The endoplasmic reticulum (ER) is responsible for the synthesis of 
secreted and integral membrane proteins, lipid production, and calcium 
homeostasis.  Little is known about targeting the ER with small molecules, but it 
has been proposed23, 60 that amphipathic and moderately lipophilic compounds 
can selectively associate with the cholesterol-poor membranes of the ER. The 
commercial fluorophore ER-Tracker Blue-White DPX is widely used for ER-
imaging, although its specific mechanism of accumulation in this organelle has 
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not been studied.61 A novel fluorophore that selectively targets and accumulates 
in the ER is described in Chapter 3 of this dissertation. 
Because of the importance of the ER in protein homeostasis, the delivery 
of protein and peptide-based agents to this organelle is of interest. In MOLT-4 
cells, ER-specific targeting was achieved by treating cells with an exogenous 
derivative of green-fluorescent protein (GFP) containing an N-terminal cell-
penetrating TAT peptide and the C-terminal ER-localization sequence KDEL.62 
This approach was used as a proof-of-concept for a dual TAT/KDEL ER-targeting 
technique. In a related strategy, some natural protein toxins hijack the cellular 
trafficking machinery, translocating the toxin from the extracellular environment 
through the Golgi apparatus and ER.63-65 One such toxin, Shiga toxin, is the 
primary virulence factor produced by S. dysenteria. This toxin binds to glycolipid 
globotriaosylceramide (Gb3, also known as CD77) on the plasma membrane.66 
Following retrograde transport to the cytosolic face of the ER membrane, Shiga 
toxin inhibits protein synthesis by catalytic removal of an adenosine from the 60S 
subunit of the ribosome.67 The ability of Shiga toxin to hijack the cellular 
trafficking machinery for ER-specific targeting has garnered interest in the 
delivery of other agents to this important organelle. When dendritic cells were 
treated with a catalytically inactive B-subunit of Shiga toxin linked to peptide 
antigens, the antigens were delivered to the ER and resulted in presentation by 
major histocompatibility complex (MHC) molecules.68-69 This approach has shown 
promise in mouse models for the development of adjuvant-free vacinations.70 
The ER-targeted delivery and release of the topoisomerase I inhibitor SN-38 was 
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demonstrated using the B-subunit of Shiga toxin, and toxicity was shown to be 
dependent on expression of the receptors Gb3/CD77.71 Because Gb3/CD77 is 
overexpressed in certain cancer cells such as B-cell lymphomas72-73 and 
colorectal carcinomas,74-75 targeting of the ER through conjugation of agents to 
Shiga toxin has promise for the development of selective anticancer therapies.76-
77 
1.3.4 The Nucleus 
The nucleus is a double-membrane enclosed organelle that houses the 
genomic DNA of eukaryotic cells. Exchange of material between the cytosol and 
the nucleus occurs through large protein-based (~120 MDa)78 nuclear pore 
complexes (NPCs).79 Small-molecules such as the common fluorescent DNA-
binding compound Hoechst 33342 and DAPI (Figure 1.3 panel C)80 can freely 
diffuse through NPCs and bind DNA in the nucleus.81 The acridine dye ICR-191 
(Figure 1.3 panel C), a mutagen commonly used in forward genetic studies, 
consists of an intercalating motif that targets the alkylating activity of the nitrogen 
mustard to DNA in the nucleus. Alkylating agents such as ICR-191 preferentially 
target guanines at the N7 position,82 and are useful for creating frame-shift 
mutations in forward genetics studies.83 Unlike small molecules, larger 
biomolecules such as proteins, RNA, and viral DNA rely on receptor-mediated 
transport through the NPC, mediated by nuclear localization and nuclear export 
peptides.84 
For cellular transfection experiments, subcellular targeting of exogenous 
DNA to the nucleus is necessary. Viral transduction using common lentiviral85-87 
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or adenoviral88-89 vectors overcomes this issue by utilizing viral pathways for 
cellular entry and delivery of the desired DNA to the nucleus. In order for genes 
of non-viral DNA to be expressed, the DNA must pass through several cellular 
barriers such as the plasma membrane or endocytic vesicles and then enter the 
nucleus through the NPC. To circumvent this issue of delivery of exogenous DNA 
into the nucleus, a variety of transfection agents have been developed. DNA 
packaged into cationic liposomes (lipoplexes) is frequently used for in vitro 
transfection, but has proved to be of limited use in vivo.90 Additionally, DNA 
complexed with positively charged amine-containing polymers can be taken up 
by cells and reach the cytosol.91 The mechanism of nuclear transport of 
uncomplexed cytosolic DNA remains unclear, but the addition nuclear-
localization sequence peptides has been shown to enhance gene expression 
through more efficient nuclear targeting.92-93 
 
1.3.5 Mitochondrial Function Enables Targeting by Small-Molecules 
The mammalian mitochondrion is a complex organelle responsible for the 
majority of cellular respiration as well as regulating cellular apoptotic signaling 
(Figure 1.4). Mitochondria are composed of two phospholipid bilayer membranes 
termed the inner and outer membrane. The outer membrane separates the 
cytosol from the inter-membrane space and is permeable to solutes less than 
5000 Da because of the presence of the membrane protein porin. The inner 
membrane is responsible for separating the inter-membrane space from the 
mitochondrial matrix and contains protein complexes involved in oxidative 
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phosphorylation. Oxidative phosphorylation (OXPHOS) establishes the 
mitochondrial membrane potential (ψm) across the inner membrane (-100 to -180 
mV, depending on cell type) consisting of a gradient of protons.94 This proton 
gradient is used by the mitochondrial F1F0-ATPase to drive synthesis of ATP 
from ADP. The mitochondrial electrochemical gradient drives the selective 
accumulation of some cationic small molecules into mitochondria.  
 
Figure 1.4. Functions of mitochondria of mammalian cells. Key features include 
the outer and inner membrane, the protein complexes of oxidative 
phosphorylation (OXPHOS), the electrochemical gradient of protons in the inner 
membrane space, the mitochondrial ATP synthase that uses the electrochemical 
gradient to produce ATP, and cytochrome C (CytC) that is released from the 
inner membrane space to the cytosol during apoptosis.  
 
Lipophilic, cationic molecules accumulate in the matrix of mitochondria by 
diffusion down the negative electrochemical potential through the inner 
membrane (Figure 1.4).94-96 This phenomena is exemplified by fluorophores 
(Figure 1.5 panel A) that selectively accumulate into polarized mitochondria such 
rhodamine esters, the commercial MitoTracker dyes (Life Technologies), and the 
hydrophobic rhodamine HR101.97 HR101 was first synthesized in the Peterson 
laboratory, and some new studies of this compound are described in Chapter 4 
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of this dissertation (Figure 1.5, panel A). These types of fluorophores retain a 
permanent positive charge, but they are lipophilic enough to freely diffuse 
through the inner membrane and down the potential of the electrochemical 
gradient to accumulate in the mitochondrial matrix. 
  
Figure 1.5. Panel A: Fluorescent probes of mitochondria employed in 
microscopy. The commercial MitoTracker dyes (Life Technologies) contain 
benzyl chloride motifs, which are useful for retention in the mitochondria following 
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Practitioners of medicinal chemistry and chemical biology can take 
advantage of the electrochemical gradient of mitochondria to design 
mitochondria-targeted agents. Examples of small molecules that accumulate in 
mitochondria can be found in Figure 1.5. Through the addition of lipophilic 
cationic groups, small molecules can accumulate in mitochondria to limit 
undesired interactions with non-mitochondrial targets. This approach was 
successfully used in targeting the HSP90 inhibitor geldanamycin to mitochondria 
to inhibit the mitochondria-specific isoform (TRAP-1) using guanidinium repeats 
or triphenylphosphonium cations (Figure 1.5 panel B).98 Triphenylphosphonium 
salts99-101 have also been used to target a number of antioxidants to the 
mitochondria such as MitoVit E (Figure 1.5, panel B). Cell-penetrating peptides 
(CPP), based on the sequence of HIV transactivator of transcription (TAT), have 
garnered interest for their ability to deliver normally cell-impermeable material 
into the cytosol.102-103 However, traditional TAT-based CPP sequences do not 
penetrate the inner mitochondrial membrane.104 New peptide sequences termed 
mitochondrial penetrating peptides (MPP, Figure 1.5 panel B), with alternating 
unnatural hydrophobic/cationic residues, have been shown to specifically deliver 
cargo through the plasma membrane and into mitochondria.105  
Certain cationic small molecules can accumulate in mitochondria without 
engineered targeting motifs. MKT-077 is a rhodacyanine derivative (Figure 1.5 
panel B) that inhibits the mitochondrial protein chaperone mortalin.106 This 
compound has been shown107 to exhibit a 4-fold selectively for targeting the 
cancer line CX-1 verses the non-cancer line CV-1. The cationic neurotoxin MPP+ 
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(1-methyl-4-phenylpyridinium, Figure 1.5 panel B) is a useful agent for creating 
animal models of Parkinson’s disease.108-111 Animals treated with the metabolic 
precursor MPTP convert MPTP to MPP+ due to the activity of monoamine 
oxidase-B (MAO-B).112 The dopamine transporter (DAT)113 causes dopaminergic 
cells selectively to accumulate MPP+, leading to selective death of dopaminergic 
cells and severe Parkinson’s symptoms. Mitochondria maintain multiple copies of 
a circular DNA of approximately 16.6 kB that is independent of genomic DNA.114 
Selective targeting of this mitochondrial DNA by the intercalator ditercalinium 
(Figure 1.5 panel B) can lead to selective loss of mitochondrial DNA verses 
genomic DNA.115-117 The ability to direct biologically active small molecules to this 
important organelle through engineered linkers or an inherent permanent positive 
charge provides unique tools for controlling biological systems. 
 
1.5 Outline of this Dissertation 
Building on a renewed interest in phenotypic discovery methods, my 
research has focused on the design, synthesis, and biological evaluation of 
fluorescent small molecules that exhibit specific patterns of subcellular 
localization and studies of their downstream biological effects. Chapter 2 
describes work redefining the mechanism of action of the potent anti-cancer/anti-
viral compound AKT inhibitor-IV (AKTIV) as a specific inhibitor of mitochondrial 
function. This chapter describes investigations of the photophysical properties of 
AKTIV as well as the effects on cellular bioenergetics and mitochondrial 
morphology. Chapter 3 describes the synthesis and biological evaluation of novel 
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fluorinated, hydrophobic rhodols that specifically accumulate in the ER and can 
deliver a cytotoxic warhead to this organelle to selectively target the ERAD 
pathway. Chapter 4 describes the discovery of two fluorescent molecular probes 
that are active in the vertebrate model organism zebrafish (Danio rerio), including 
hydrophobic rhodamines targeted to mitochondria and acid-activated 
fluorophores that accumulate in acidic tissues. Chapter 5 describes an unrelated 
project involving the synthesis of novel dimers of cholesterol and in vitro stability 
analysis of liposomes that incorporate these compounds. 
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The Anticancer/Antiviral Agent Akt Inhibitor-IV Massively Accumulates in  
Mitochondria and Potently Disrupts Cellular Bioenergetics 
 
2.1 Introduction 
Akt inhibitor-IV (ChemBridge 5233705, CAS 681281-88-9, AKTIV, Figure 2.1 
Panel A), a cationic benzimidazole derivative, exhibits a wide range of biological 
activities. This small molecule was first identified in a chemical genetic screen as an 
inhibitor of nuclear export of the FOXO1a protein.1 In U2OS cancer cells, low 
concentrations of AKTIV (IC50 = 0.625 µM) blocked nuclear export of this protein with 
concomitant inhibitory effects on cellular proliferation (IC50 < 1.25 µM).1  At a higher 
concentration of 10 µM, phosphorylation of the serine-threonine kinase Akt (protein 
kinase B) on residues Ser473 and Thr308 was suppressed. Because phosphorylation of 
FOXO1a by Akt promotes nuclear export, AKTIV was initially proposed to block nuclear 
export of FOXO1a by inhibiting a kinase in the PI3-kinase (PI3K) / Akt pathway.1  Other 
studies of AKTIV confirmed its potent cytotoxic activity (typical IC50 values < 2 µM) 
against a wide range of cancer and other cell lines.2-7 Although some inhibitors of the 
PI3K / Akt pathway show promise as anticancer agents,8-9 more recent studies10 of 
AKTIV concluded that this compound does not directly block the activity of any known 
kinases within this signaling cascade. Moreover, this compound paradoxically increases 
phosphorylation of Akt when added to BHK-21 cells at 1-2 µM.10 High concentrations 
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(10 µM) of this small molecule also activate the unfolded protein response (UPR) and 
trigger cellular blebbing and apoptosis in HEK293T cells.11 
In addition to its major effects on cellular proliferation, AKTIV exhibits broad-
spectrum antiviral activity. Viruses inhibited by this compound include vesicular 
stomatitis virus (VSV), respiratory syncytial virus, vaccinia virus in infected BHK-21 
cells,10 and parainfluenzavirus-5 (PIV5) in infected HeLa cells.12-14 However, the 
mechanistic basis for this activity is not well understood, the importance of the PI3K / 
Akt pathway in viral replication is controversial, and AKTIV has been reported to block 
the replication of negative-strand RNA viruses through an Akt-independent 
mechanism.10 The antiviral effects of AKTIV also appear to be independent of its 
cytotoxic effects on host cells. 
To probe the structural features associated with this highly biologically active 
scaffold, we previously reported the synthesis of AKTIV and a collection of analogues.13  
We demonstrated that this compound and some analogues exhibit selective anticancer 
activity against human HeLa carcinoma cells when compared with normal human 
bronchial/tracheal epithelial (NBHE) cells. We further confirmed its antiviral effects 
against recombinant parainfluenzavirus-5 in HeLa cells. Although the photophysical 
properties of these compounds have not been previously characterized, during our prior 
synthesis of analogues of AKTIV, we noticed that some of these compounds were 
qualitatively fluorescent in solution, and this observation led to the hypothesis that 
studies of the intrinsic fluorescence of Akt inhibitor-IV, like other fluorescent molecular 
probes,15-16 might reveal its biological mechanism of action. We report here an 
investigation of the mechanism of action of AKTIV that exploits the intrinsic fluorescence 
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of this small molecule. This approach revealed that AKTIV rapidly accumulates to high 
levels in mitochondria of treated mammalian cells and profoundly affects the 
morphology of these organelles. Treatment of cancer cell lines with AKTIV rapidly 
triggers extensive mitochondrial dysfunction, and this new understanding of its 
mechanism of action explains many of the diverse biological activities of this potent 
small molecule. 
 
Figure 2.1. Panel A: Chemical structure of AKTIV. Panel B: The absorbance (Abs.), 
excitation (Ex.), and fluorescence emission (Em.) spectra of AKTIV obtained in PBS (pH 
7.4) and ethanol. Panel C: Values for the extinction coefficient (ε), and quantum yield 
(Φ) in PBS of AKTIV.  
 
2.2 Photophysical Properties of AKTIV 
During our prior studies of AKTIV,13 we observed that dilute solutions of this 
compound are fluorescent when irradiated with ultraviolet light. To examine the 
photophysical properties of this compound in detail, we obtained absorbance, 
fluorescence excitation, and fluorescence emission spectra in aqueous buffer (PBS, pH 
7.4) and ethanol. As shown in Figure 2.1 (Panel B), the spectral properties of AKTIV in 
both of these solvents were very similar, indicating that unlike some common 
fluorophores, such as dansyl, NBD, and certain coumarins,17 its fluorescence properties 
are not highly sensitive to environmental conditions. In these solvents, AKTIV was found 
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to strongly absorb in the UV–violet region (absorbance λmax, PBS = 390 nm), with a 
relatively high extinction coefficient (ε390 nm) in PBS of 54,000 M-1 cm-1. Upon excitation 
with UV (λmax, ex. = 388 nm, Figure 2), AKTIV emitted blue fluorescence with λmax = 460 
nm (Figure 2.1, panel B). However, the quantum yield (Φ) of AKTIV was only 0.0016, as 
determined by comparison with the integrated emission of the coumarin-derived 
fluorophore Pacific Blue (Φ= 0.75, λmax,abs. = 405 nm, λmax, em. = 450 nm).18,19 When the 
brightness of these two fluorophores was compared, defined as the product of the 
quantum yield and extinction coefficient, AKTIV was 260-fold less bright than Pacific 
Blue (ε405 nm = 30,000 M-1 cm-1).19 However, the relatively close match of the maximal 
excitation wavelength (388 nm) of AKTIV to the 405 nm laser line of many confocal 
laser scanning microscopes and flow cytometers led us to conclude that the intrinsic 
fluorescence of this compound might enable imaging and analysis of its subcellular 
distribution in living mammalian cells. 
 
2.3 Confocal Laser Scanning Microscopy of Cells Treated With AKTIV  
To investigate the utility of AKTIV as a fluorescent probe, HeLa cervical 
carcinoma cells were briefly treated (5 min, no wash step) with a low concentration (1 
µM) of this compound. Imaging by confocal laser scanning microscopy, with excitation 
at 405 nm, revealed fluorescence in defined subcellular structures of treated cells 
(Figure 2.2, panel A). These structures exhibited a tubular morphology and were 
identified as mitochondria by co-staining with the spectrally orthogonal probe 
MitoTracker DeepRed. To examine if autofluorescence of NADH20 in these organelles 
contributed to this signal,  control experiments in the absence of AKTIV were used to 
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verify that the fluorescence observed in mitochondria upon excitation at 405 nm was 
exclusively derived from this compound (Figure 2.2, panel B). Because of its low 
quantum yield, the visualization of AKTIV in mitochondria of treated HeLa cells 
suggested that this compound accumulates to high levels in these organelles.  
  
 
Figure 2.2. Confocal laser scanning and differential interference contrast (DIC) 
micrographs of living HeLa cells. Cells in Panel A were treated with MitoTracker DR 
(100 nM) and AKTIV (1 µM) for 5 min. Cells in Panel B were treated with MitoTracker 







2.4  Quantification of AKTIV in Mitochondria 
As shown in Figure 2.3, AKTIV shows structural similarities to MitoTracker Deep 
Red-FM,21 JC-1,22 rhodamine 123,23, MKT-007,24-25 and F16.26 These types of lipophilic 
delocalized cations are known to accumulate in mitochondria27-28 and are driven into 
this organelle by the high negative electrochemical potential that exists across the inner 
mitochondrial membrane (typically –120 to –180 mV, depending on cell type).29-32  
! 
Figure 2.3. Comparison of the structure of AKTIV with other small molecules that 
selectively accumulate in mitochondria of mammalian cells. 
 
 To quantify the extent of bioaccumulation of small molecules in mitochondria, we 
initially analyzed the fluorescence of bead standards upon excitation at 405 nm and 488 
nm. This allowed standard curves of molecular equivalents of the fluorophores Cascade 
Blue (for AKTIV) and fluorescein (for rhodamine 123) to be constructed. Human Jurkat 
cells were briefly treated with AKTIV or rhodamine 123 for 15 min, subjected to flow 
cytometry under the same conditions, and the number of fluorophores per cell was 
calculated based on the brightness of Cascade Blue (Φ= 0.54, ε399 nm = 28,000 M-1 cm-
1)33 and fluorescein (ΦpH 9 = 0.93, ε490 nm = 76,900 M-1 cm-1).34 As shown in Figure 2.4, 
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based on the published35 average cell volume (663.7 µm3) and mitochondrial volume 
(33.4 µm3) of Jurkat lymphocytes, concentrations of rhodamine 123 and AKTIV in 
mitochondria were determined. These studies revealed that after treatment of cells with 
culture media containing 0.05 to 5 µM of these compounds, rhodamine 123 reached 
concentrations of 1–548 µM in mitochondria.  Under the same conditions, AKTIV 
accumulated to 17–1,435 µM in these organelles. Correspondingly, when 1 µM of 
AKTIV was added to cells for 15 minutes, over 250-fold bioaccumulation in mitochondria 
was observed. A 250-fold accumulation represents a ΔE ~147 mV (Nerst equation), 
which is similar to typical resting mitochondrial membrane potentials. This level of 
mitochondrial accumulation is consistent with data on other lipophilic cations.36-37 This 
rapid, selective, and massive accumulation in mitochondria provides strong evidence 
that these organelles may be a major and direct target of the biological effects of this 
small molecule.   
 
Figure 2.4. Concentrations of rhodamine 123 and AKTIV in mitochondria of Jurkat 
lymphocytes after treatment for 15 minutes at 37 °C. Treated cells were analyzed by 
flow cytometry with excitation at 488 nm (rhodamine 123) or 405 nm (AKTIV). Cellular 
fluorescence was converted to concentration using a standard curve constructed with 
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SpheroTech Rainbow Ultra beads and a ratio of mitochondrial volume to total cell 
volume of 0.053. Error bars represent the standard deviation. 
 
2.5  Changes in Mitochondrial Morphology upon Treatment with AKTIV 
 To probe the effects of AKTIV on mitochondria, we examined the morphology of 
these organelles in HeLa cells by confocal laser scanning microscopy. In living cells, 
mitochondria constantly undergo fusion and fission events on the timescale of several 
minutes, and these dynamic processes play key roles in mitochondrial biogenesis, 
cellular energetics, apoptosis, and mitochondrial morphology.38-39 Compared to the 
vehicle (0.1% DMSO) control, when HeLa cells were treated with AKTIV (1 µM) for 20 
min, rapid and extensive swelling of the normally tubular mitochondria was observed 
(Figure 2.5, compare panel D-F). This swelling was followed by similarly rapid 
disintegration of these organelles into smaller structures. As a positive control, hydrogen 
peroxide was used to induce oxidative stress and disrupt the mitochondrial network.40 In 
HeLa cells treated with H2O2 (1 mM) for 20–40 minutes, fragmentation of the 
mitochondrial network was observed, but this treatment did not cause the swelling or 
disintegration associated with AKTIV (Figure 2.5). These results indicate that AKTIV 
profoundly disrupts the morphology of mitochondria of HeLa cells, inducing distinctive 




Figure 2.5. Confocal laser scanning micrographs of living HeLa cells treated with 
Mitotracker Deep Red FM (100 nM). Cells were further treated with DMSO (0.1%, 
Panels A–C), AKTIV (1 µM, Panels D–F), or hydrogen peroxide (1 mM, panels G–I) at 
37 °C. The same field of cells was imaged at the three times shown. Scale bar = 20 µm. 
 
2.6 Cellular Toxicity Induced by AKTIV 
Elevated mitochondrial membrane potential is a hallmark of cancer.30, 41-42 To 
examine the effect of AKTIV on cell lines that differ in mitochondrial membrane 
potential, we compared the toxicity of this compound with an uncharged desethyl 
analogue (DEAKTIV)13 towards two cancer cell lines (HeLa and Jurkat) and the normal 
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monkey kidney cell line CV-1. The DEAKTIV analogue was chosen as a control 
because it lacks the fixed positive charge needed to drive accumulation into 
mitochondria. DEAKTIV is weakly basic (calculated pKa = 4.5) relative to the more basic 
environment of the mitochondrial lumen (~pH 8.0). As shown in Figure 2.6 (Panel A), 
AKTIV was highly toxic towards HeLa (IC50 = 320 ± 30 nM) and Jurkat (IC50 = 340 ± 30 
nM) cells, but this compound was less toxic towards normal CV-1 cells (IC50= 870 ± 90 
nM), which have been shown to exhibit a lower inherent mitochondrial membrane 
potential.43 The uncharged but structurally similar DEAKTIV analogue was not toxic to 
any of these cell lines (IC50 > 10 µM), providing evidence that the positive charge of 
AKTIV drives this compound into mitochondria. 
 
2.7 Depolarization of the Mitochondrial Electrochemical Gradient by AKTIV 
 To examine the functional consequences of treatment with AKTIV, the 
fluorescent probe JC-1 (Figure 2.3) was used to measure effects on the membrane 
potential of mitochondria. This probe undergoes a shift in fluorescence emission from 
green to red as it accumulates in mitochondria, and by analysis of this red/green ratio, 
one can quantify the extent of mitochondrial depolarization. As shown in Figure 2.6 
(Panel B), treatment with AKTIV for 2 h depolarized mitochondria of HeLa cells (IC50= 
920 ± 30 nM) and Jurkat cells (IC50= 750 ± 30 nM) at submicromolar concentrations, 





Figure 2.6. Panel A: Cytotoxicity of AKTIV and the uncharged DEAKTIV analogue 
towards two cancer cell lines (HeLa, Jurkat) and a normal cell line (CV-1) after 48 h. 
Panel B: Effect of these compounds on the polarization of mitochondria as assayed with 
the ratiometric fluorescent probe JC-1 (1 µM). 
 
2.8 Inhibition of Cellular Respiration by AKTIV 
 Mitochondria predominantly produce cellular ATP during aerobic respiration.30 To 
determine whether AKTIV inhibits this process, we used a MitoXpress Xtra-HS assay 
(Luxcel) to measure the consumption of oxygen by mitochondria in HeLa cells (Figure 
2.7, panel A). This commercial assay uses an immobilized platinum-containing 
porphyrin fluorophore that is quenched upon binding oxygen, allowing monitoring of 
changes in extracellular oxygen over time.44  Consistent with previous studies,45 
carbonyl cyanide 3-chlorophenylhydrazine (CCCP), an uncoupling agent that disrupts 
mitochondrial electron transport chain activity by bypassing efflux of protons through the 
ATP synthase complex, accelerated consumption of O2 compared to vehicle control. In 
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contrast, AKTIV (2 µM) completely blocked consumption of O2 over the 90-minute time 
course of the experiment. This inhibition was comparable to treatment with 10 µM of the 
mitochondrial complex I inhibitor rotenone.45 Addition of LY294002 (10 µM), a well-
characterized inhibitor of PI3K/Akt pathway,46 showed no effect on O2 consumption, 
demonstrating that blocking this pathway under these conditions does not affect 
mitochondrial respiration. This control experiment provides evidence that the inhibition 
of mitochondrial respiration by AKTIV is upstream of the PI3K/Akt pathway. 
  
2.9 Induction of Reactive Oxygen Species by AKTIV 
 Reactive oxygen species (ROS) are byproducts of the mitochondrial electron 
transport chain.47 Premature leakage of electrons from OXPHOS complexes can lead to 
production of superoxide (O3-) by one-electron reduction of molecular oxygen.48-49 
Superoxide is typically transformed into two molecules of hydrogen peroxide by 
superoxide dismutase, which can be further transformed by catalase into molecular 
oxygen and water.50 However, superoxide or hydrogen peroxide that escapes this 
detoxification pathway can lead to direct damage of proteins, lipids, and DNA.48-49, 51 
High levels of ROS indicate mitochondrial dysfunction and can induce apoptosis.51 To 
investigate whether treatment with AKTIV induces changes in cellular ROS, which could 
link mitochondrial dysfunction to downstream redox-sensitive biological effects such as 
activation of Akt,52 we assayed levels of ROS in Jurkat lymphocytes with the fluorescent 
probe H2DCFDA. As shown in Figure 2.7 (Panel B), treatment of Jurkat cells with AKTIV 
(30 min) increased cellular ROS in a dose-dependent manner by up to 59-fold at 2 µM 
compared with the vehicle control. Treatment with hydrogen peroxide (30 min) as a 
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positive control increased ROS by 24-fold at 1 µM and 93-fold at 10 µM. Higher 
concentrations of hydrogen peroxide (50 µM) showed reduced effects that were 
associated with cytotoxicity. As another control, treatment with rotenone (30 min), an 
agent previously shown to elevate cellular ROS in HepG2 cells,53 increased ROS in a 
dose-dependent manner by up to 16-fold at 50 µM. Given that phosphorylation of Akt is 
redox-sensitive,52 and can be activated by treatment of cells with hydrogen peroxide, 
these results suggest that the mitochondrial dysfunction and production of ROS by 
AKTIV may be mechanistically linked to the previously reported10 activation of Akt.  
 
 
Figure 2.7. Panel A: Consumption of oxygen by HeLa cells over a 90-minute period 
quantified by time-resolved fluorescence with a MitOXpress XS assay. Panel B: 
Fluorescence of the ROS sensor H2DCFDA (2 µM) in Jurkat cells. Cells were treated 
for 30 minutes followed by analysis by flow cytometry. Error bars represent standard 
errors of the mean. 
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2.10 Conclusions 
Based on its effects on the nuclear export of FOXO1a, AKTIV was initially 
proposed1 to function as an inhibitor of the PI3K/Akt pathway. However, a more recent 
investigation by Connor10 concluded that this compound does not inhibit any known 
kinases in this signaling pathway; moreover, AKTIV increases phosphorylation of Akt 
kinase when added to BHK-21 cells at concentrations that elicit major biological effects. 
To investigate its mechanism of action, we used intrinsic fluorescence to examine the 
subcellular localization of AKTIV. Imaging of treated HeLa cells by confocal microscopy 
with excitation at 405 nm revealed mitochondria as a major target of this potent 
anticancer/antiviral agent. When cancer cell lines were treated with 0.5 µM of this 
compound, AKTIV rapidly accumulated by over 250-fold in these organelles compared 
to media concentrations within 15 minutes (Figure 2.4) and caused profound 
mitochondrial dysfunction. Low concentrations of AKTIV triggered swelling, 
disintegration, and depolarization of mitochondria, elevation of ROS, and essentially 
complete inhibition of cellular consumption of oxygen. This rapid elevation of ROS 
provides a potential mechanistic link between mitochondrial dysfunction induced by 
AKTIV and increased phosphorylation10 of the redox-sensitive52 Akt kinase observed at 
low concentrations. These studies revealed a potentially novel mechanism of action of 
AKTIV that may provide a new rationale for its anticancer and broad-spectrum antiviral 
activities.  
Because of altered glucose metabolism, cancer cells commonly exhibit elevated 
mitochondrial membrane potentials of at least 60 mV (negative inside) compared with 
normal cells.30, 41-42 By accumulating in hyperpolarized mitochondria, delocalized 
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lipophilic cations such as rhodamine 123,23, 43 dequinalinium,54 F16,26 MKT-07724-25 
rosamines,55 and others27, 56-57-58 can exhibit selective anticancer activity.59-60 These 
types of compounds can affect a number of different mitochondrial targets involved in 
cellular proliferation including mitochondrial polarization,26 the NADH-ubiquinone 
reductase,61 the F0F1 ATPase,27 and pro-apoptotic signals such as Bcl-2 family 
members.62 Consequently, the selective anticancer activity of AKTIV is consistent with 
its profound effects on hyperpolarized mitochondria in the absence of downstream 
effects on the PI3K/Akt pathway. 
Inhibitors of mitochondrial respiration suppress the de novo synthesis of 
pyrimidines.63 This mechanism of action was recently reported64 to be responsible for 
the broad spectrum antiviral activity of the natural product antimycin A, a mitochondrial 
complex III inhibitor, against RNA viruses. This antiviral activity of antimycin A and 
analogues was observed at nanomolar concentrations that are not toxic to mammalian 
host cells. Other compounds similarly shown to exhibit antiviral activity by promoting 
mitochondrial dysfunction include the complex III inhibitor myxothiazole, the complex I 
inhibitor rotenone, the proton ionophore CCCP, and the ATP synthase inhibitor 
oligomycin.64 Some of these mitochondrial electron transport chain inhibitors exhibit 
antiviral activity under conditions where ATP production is not supressed.64 Based on 
this precedent, we conclude that the broad spectrum antiviral activity of AKTIV relates to 
its immediate and direct effects on mitochondria either through suppression of de novo 
synthesis of pyrimidines, the generation of mitochondrial ROS, and/or depletion of 
cellular ATP. Consequently, the discovery that mitochondria, a major target of AKTIV, 
are profoundly affected within minutes of treatment of cells at concentrations of 1 µM or 
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less, provides a unifying explanation for many of the diverse biological activities of this 
potent small molecule. Future work to indentify a specific molecular target(s) of AKTIV 
in mitochondria would be of interest to define the profound cellular effects observed. In 
future work, forward and reverse genetics, as well as proteomic studies, could be 
explored to better explain the mechanism of this potent small molecule.  
 
2.11 Experimental Methods 
2.11.1 Spectroscopy. AKTIV and DEAKTIV were prepared as previously reported.65 
Samples were analyzed in a quartz SUPRASIL Macro/Semi Micro cuvette (PerkinElmer, 
B0631132). Absorbance measurements employed an Agilent 8453 UV-Vis instrument 
and are baseline corrected. Emission spectra were acquired with a PerkinElmer LS 55 
Fluorescence Spectrometer. Extinction coefficients (ε) were determined using Beer’s 
law plots of absorbance as a function of concentration in PBS (pH 7.4) containing 
Triton-X 100 (1%). Linear regression (GraphPad Prism 5.0) provided the molecular 
absorptivity (M-1 cm-1) using the equation: Absorbance = ε[concentration (M)]L, where L 
is the path length in cm. Relative quantum yields (Φ) were determined as previously 
described.18 Briefly, the integrated fluorescence emission (410-700 nm) of both AKTIV 
and Pacific Blue were plotted as a function of A390. The ratio of the slopes from the 
resulting linear regression (GraphPad Prism 5.0), and the published quantum yield of 
Pacific Blue (0.75),66 was used to determine ΦAKTIV Ex. 390 nm as slopeA/slopeB = ΦA/ΦB. 
Measurements were in triplicate. 
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2.11.2 Cell Culture. Jurkat (TIB-152), HeLa (CCL-2), and CV-1 (CCL-70) cell lines were 
obtained from ATCC and cultured in a humidified CO2 (5%) incubator at 37 °C. 
Dulbecco’s Modified Eagle Medium (DMEM, Sigma D5796) and RPMI-1640 (Sigma 
R8758) were supplemented with FBS (10%, Sigma F0926), penicillin (100 units/L), and 
streptomycin (100 µg/L, Sigma P4333).  
 
2.11.3 Microscopy. Prior to treatment with compounds, adherent cells in DMEM were 
added to an 8-well cover glass slide (Idibi µ-Slide, 200 µL, 20,000 cells/well) and 
allowed to proliferate for 24 h. Compounds in concentrated DMSO stock solutions were 
diluted 1000-fold with complete media prior to addition to cells. Cells labeled with 
MitoTracker Deep Red FM (MTDR, Life Technologies) were treated with this 
fluorophore (100 nM, 15 min), washed with complete media, and subsequently treated 
with AKTIV (1 µM, 5 min) without further washing. Cells were imaged using a Leica 
SPE2 confocal laser-scanning microscope fitted with a 63X objective. AKTIV was 
excited with a 405 nm laser and emitted photons were collected from 415 nm to 480 
nm. MTDR was excited with a 635 nm laser and emitted photons were collected from 
645 nm to 700 nm. For the time-lapse experiments shown in Figure 2.5 and the 
supporting videos, a 635 nm laser was exclusively used for excitation, and images of 
the same field of cells were generated every minute for 30 to 40 min. In figures with 
multiple panels of images, the microscope settings and image processing parameters 
for each panel were identical. 
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Figure 2.8. Confocal laser scanning and DIC micrographs of HeLa cells treated with 
MitoTracker Deep Red FM (MTDR), CCCP, and AKTIV. Compounds were added to 
living cells on a cover glass on the inverted microscope. The before and after images of 
the same field of cells validate the specific fluorescent signals are not due to differences 
in the field of cells selected. Rapid depolarization of mitochondria by CCCP inhibits 
cellular uptake of AKTIV (compare panels B with E). Scale bar = 25 µm. 
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2.11.4 Quantification of Accumulation of Small Molecules in Mitochondria. Jurkat 
cells (1 mL, 250,000 cells) were treated in duplicate with complete RMPI medium 
containing AKTIV or rhodamine 123 (0.1% DMSO) for 15 minutes at 37 °C. Cells were 
washed with Hank’s Balanced Salt Solution (HBSS, Mediatech Inc). Jurkat cells treated 
with rhodamine 123 were analyzed with an Accuri C6 flow cytometer (488 nm excitation, 
530 ± 15 nm emission). Jurkat cells treated with AKTIV were analyzed with a BD LSR II 
flow cytometer (405 nm excitation, 450 ± 25 nm emission).  Standard curves for 
molecular equivalents of fluorescein (MEFL) and cascade blue (MECSB) were created 
using 6-peak Ultra Rainbow Calibration Beads (Spherotech). Molecular equivalents of 
AKTIV (MEAKTIV) were obtained by multiplying MECSB values by 257 to correct for the 
relative brightness (ε*Φ) of AKTIV (ε390= 54,000 M-1cm-1, Φ= 0.0016, A405/A390 = 0.68) 
compared with Cascade Blue (ε399= 28,000 M-1cm-1, Φ= 0.54). The emission of AKTIV 
and Cascade Blue was very similar under these conditions.33 MEFL values from cells 
treated with rhodamine 123 were converted into molecular equivalents of rhodamine 
123 (MERho123) by mulitiplication by 1.03 to correct for differences in relative 
brightness of these fluorophores. This MEFL/MERho123 correction factor (1.03) was 
obtained by integration (515-545 nm) of the emission spectra of solutions of both 
fluorescein and rhodamine 123 (25 nM) in PBS (pH = 7.4) upon irradiation at 488 nm, 
using excitation and emission windows that match the flow cytometer. MEAKTIV and 
MERho123 values were converted into concentration in mitochondria by conversion to 
moles (molecular equivalents/Avogadro’s number) and published35 values for the 
average volume of a Jurkat cell (663.7  µm3) and the ratio (0.053) of mitochondrial 
volume to total cell volume. To account for quenching of fluorophores at high 
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concentrations in mitochondria, as shown in Figure S1, multiplication factors were 
generated based on differences between plots of linear and exponential functions at 
different fluorophore concentrations. These factors were used to correct the measured 
concentrations of AKTIV and rhodamine 123 in mitochondria due to fluorescence 
quenching. Untreated cells were used for baseline corrections to eliminate any potential 
contributions from autofluorescence. 
 
Figure 2.9. Concentration-dependent quenching of the fluorescence emission of AKTIV 
and rhodamine 123 in ethanol. The fluorophores were excited at 405 nm (AKTIV) or 488 
nm (rhodamine 123) to match the laser lines used in flow cytometry studies of living 
cells. Emission spectra, at wavelengths analyzed by flow cytometry, were generated as 
shown in Panels A and B (a 1% transmission attenuator was used to filter the emission 
of rhodamine 123). These emission windows were integrated and the areas under the 
curve (AUC) were plotted as shown in Panels C and D. Linear regression was used to 
fit the data for concentrations of 5 µM and lower, where fluorescence quenching was not 
observed, whereas quenching of the fluorescence observed at higher concentrations 
was fit to a one-phase exponential association model (R2>0.99, GraphPad Prism 6 
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software). Differences between these functions were used to correct for quenching of 
fluorophores at elevated concentrations in mitochondria. 
 
2.11.5 Cytotoxicity Assays. HeLa and CV-1 cells (150 µL, 4,000 cells) in complete 
DMEM were added to a 96-well plate (CytoOne, CC7682-7596) and allowed to 
proliferate for 24 h. This medium was replaced with complete DMEM containing AKTIV 
or DEAKTIV (0.1% DMSO). Jurkat cells (150 µL, 4,000 cells) were suspended in 
complete RPMI medium containing AKTIV or DEAKTIV (0.1% DMSO) on a 96-well 
plate. These plates were incubated for 48 h at 37 °C. Following incubation, HeLa and 
CV-1 wells were washed with PBS (200 µL), treated with trypsin (50 µL) for 5 min, 
followed by DMEM (100 µL) containing propidium iodide (3 µM, PI). Cellular viability 
was measured with an Accuri C6 flow cytometer by analysis of light scattering and 
cellular uptake of PI. Jurkat cells were pelleted in eppendorf tubes (0.5 mL), the 
supernatant was removed, and the media was replaced with fresh RMPI containing PI 
(2 µM) prior to analysis by flow cytometry. Total cell counts were normalized between 0 
and the average of the vehicle-treated (0.1% DMSO) samples. IC50 values were 
calculated using non-linear regression (GraphPad Prism 6.0 with a four-parameter 
model). The calculated pKa for DEAKTIV was done calculated with ChemAxon 
MarvinView 6.2. 
 
2.11.6 Analysis of Effects on Polarization of Mitochondria. The ratiometric JC-1 
fluorophore (Life Technologies) was used to determine effects on mitochondrial 
membrane potential. HeLa cells were plated 24 h in advance on a 24-well plate (1 mL of 
complete DMEM, 200,000 cells). Jurkat cells (1 mL of complete RPMI, 250,000 cells) 
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were plated immediately prior to the assay. JC-1 (1 µM, 0.1% DMSO) was added and 
cells were incubated at 37 °C for 30 min. Jurkat cells were pelleted and washed with 
fresh medium. HeLa cells were washed with PBS (200 µL), treated with trypsin (0.25%, 
200 µL) for 5 min at 37 °C, followed by addition of complete DMEM (800 µL) to create a 
cell suspension. Cell solutions were analyzed by flow cytometry (Accuri C6) with 
excitation at 488 nm. Analysis of light scattering was used to eliminate cell debris. 
Mitochondrial polarization was measured as the red-to-green ratio of cellular 
fluorescence calculated for each treatment. Ratios were normalized between the vehicle 
control (0.1% DMSO) and CCCP (50 µM) as a positive control. IC50 values were 
calculated by non-linear regression (GraphPad Prism 6.0 using a four parameter 
model). 
 
2.11.7 Analysis of Oxygen Consumption by Mitochondria. MitoXpress-Xtra HS 
(Luxcel) was used to assay cellular consumption of O2. HeLa cells were treated with 
trypsin-EDTA (3 mL, 0.25%) for 5 min at 37 °C to create a suspension. Complete 
DMEM (12 mL) was added. The cells were pelleted (2000 rpm, 2 min), the supernatant 
was removed, and the cells were re-suspended at 5000 cells / µL of media. This 
suspension of HeLa cells (50 µL, 250,000 cells) was added to each well of a black, 
clear-bottomed 96-well plate. A stock solution of the Pt-porphyrin probe MitoXpress-Xtra 
HS in water (10 µL, 1 µM) was added to each well. Concentrated (1.5 X) solutions of 
compounds in complete DMEM were added to achieve the desired concentrations in 
each well. To each well, the compound in complete DMEM (0.1 mL) was added. Each 
well was sealed with MitoXpress HS mineral oil (80 µL), the plate was transferred to a 
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pre-warmed (37 °C) plate reader (SpectraMax M5, Molecular Devices), and incubated 
for 30 min. Time-resolved fluorescence readings were obtained using excitation at 380 
nm, emission at 650 nm, and a 630 nm long pass filter. Time-resolved parameters were 
set at a 50 µs delay and a 100 µs integration gate. Measurements were taken every 
minute for 90 min. Compounds were evaluated in duplicate. Results were plotted 
(GraphPad Prism 6.0) and were baseline corrected using the average of the first three 
data points for each well. 
 
2.11.8 Measurement of Reactive Oxygen Species. Jurkat lymphocytes in HBSS 
(480,000 cells/mL) were treated with freshly prepared H2DCFDA (2 µM, 0.1% DMSO) 
at 37 °C for 30 min. These cells were pelleted, washed with complete RPMI medium, 
and treated with compounds (120 µL of complete RPMI, 50,000 cells) in duplicate. 
Cellular fluorescence was measured with an Accuri C6 flow cytometer after 30 min. 




1. Kau, T. R.; Schroeder, F.; Ramaswamy, S.; Wojciechowski, C. L.; Zhao, J. J.; 
Roberts, T. M.; Clardy, J.; Sellers, W. R.; Silver, P. A., A chemical genetic screen 
identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in 
PTEN-deficient tumor cells. Cancer cell 2003, 4 (6), 463-476. 
2. Koeller, K. M.; Haggarty, S. J.; Perkins, B. D.; Leykin, I.; Wong, J. C.; Kao, M. C.; 
Schreiber, S. L., Chemical genetic modifier screens: small molecule trichostatin 
 61 
suppressors as probes of intracellular histone and tubulin acetylation. Chem. Biol. 2003, 
10 (5), 397-410. 
3. Margalit, D. N.; Romberg, L.; Mets, R. B.; Hebert, A. M.; Mitchison, T. J.; Kirschner, 
M. W.; RayChaudhuri, D., Targeting cell division: small-molecule inhibitors of FtsZ 
GTPase perturb cytokinetic ring assembly and induce bacterial lethality. Proc. Natl. 
Acad. Sci. U.S.A. 2004, 101 (32), 11821-11826. 
4. Koomoa, D. L.; Yco, L. P.; Borsics, T.; Wallick, C. J.; Bachmann, A. S., Ornithine 
decarboxylase inhibition by alpha-difluoromethylornithine activates opposing signaling 
pathways via phosphorylation of both Akt/protein kinase B and p27Kip1 in 
neuroblastoma. Cancer. Res. 2008, 68 (23), 9825-9831. 
5. Hu, C.; Solomon, V. R.; Ulibarri, G.; Lee, H., The efficacy and selectivity of tumor cell 
killing by Akt inhibitors are substantially increased by chloroquine. Bioorg. Med. Chem. 
2008, 16 (17), 7888-7893. 
6. Conley-LaComb, M. K.; Saliganan, A.; Kandagatla, P.; Chen, Y. Q.; Cher, M. L.; 
Chinni, S. R., PTEN loss mediated Akt activation promotes prostate tumor growth and 
metastasis via CXCL12/CXCR4 signaling. Mol. Cancer 2013, 12 (1), 85. 
7. Takamatsu, R.; Takeshima, E.; Ishikawa, C.; Yamamoto, K.; Teruya, H.; Heuner, K.; 
Higa, F.; Fujita, J.; Mori, N., Inhibition of Akt/GSK3beta signalling pathway by Legionella 
pneumophila is involved in induction of T-cell apoptosis. Biochem. J. 2010, 427 (1), 57-
67. 
8. Fruman, D. A.; Rommel, C., PI3K and cancer: lessons, challenges and opportunities. 
Nat. Rev. Drug Discov. 2014, 13 (2), 140-156. 
 62 
9. Garcia-Echeverria, C.; Sellers, W. R., Drug discovery approaches targeting the 
PI3K/Akt pathway in cancer. Oncogene 2008, 27 (41), 5511-5526. 
10. Dunn, E. F.; Fearns, R.; Connor, J. H., Akt inhibitor Akt-IV blocks virus replication 
through an Akt-independent mechanism. J. Virol. 2009, 83 (22), 11665-11672. 
11. Blaustein, M.; Perez-Munizaga, D.; Sanchez, M. A.; Urrutia, C.; Grande, A.; Risso, 
G.; Srebrow, A.; Alfaro, J.; Colman-Lerner, A., Modulation of the Akt pathway reveals a 
novel link with PERK/eIF2alpha, which is relevant during hypoxia. PLoS One 2013, 8 
(7), e69668. 
12. Sun, M.; Fuentes, S. M.; Timani, K.; Sun, D.; Murphy, C.; Lin, Y.; August, A.; Teng, 
M. N.; He, B., Akt plays a critical role in replication of nonsegmented negative-stranded 
RNA viruses. J. Virol. 2008, 82 (1), 105-114. 
13. Sun, Q.; Wu, R.; Cai, S.; Lin, Y.; Sellers, L.; Sakamoto, K.; He, B.; Peterson, B. R., 
Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV. 
J Med Chem 2011, 54 (5), 1126-39. 
14. Luthra, P.; Sun, D.; Wolfgang, M.; He, B., AKT1-dependent activation of NF-kappaB 
by the L protein of parainfluenza virus 5. J. Virol. 2008, 82 (21), 10887-10895. 
15. Lavis, L. D.; Raines, R. T., Bright building blocks for chemical biology. ACS 
chemical biology 2014, 9 (4), 855-866. 
16. Lavis, L. D.; Raines, R. T., Bright ideas for chemical biology. ACS chemical biology 
2008, 3 (3), 142-155. 
17. Loving, G. S.; Sainlos, M.; Imperiali, B., Monitoring protein interactions and 
dynamics with solvatochromic fluorophores. Trends Biotechnol. 2010, 28 (2), 73-83. 
 63 
18. Williams, A. T.; Winfield, S. A., Relative Fluorescence Quantum Yields Using a 
Computer-controlled Luminescence Spectrometer. Analyst 1983, 108, 1067-1071. 
19. Sun, W. C.; Gee, K. R.; Haugland, R. P., Synthesis of novel fluorinated coumarins: 
excellent UV-light excitable fluorescent dyes. Bioorg. Med. Chem. Lett. 1998, 8 (22), 
3107-3110. 
20. Rodrigues, R. M.; Macko, P.; Palosaari, T.; Whelan, M. P., Autofluorescence 
microscopy: a non-destructive tool to monitor mitochondrial toxicity. Toxicol. Lett. 2011, 
206 (3), 281-288. 
21. Shim, S. H.; Xia, C.; Zhong, G.; Babcock, H. P.; Vaughan, J. C.; Huang, B.; Wang, 
X.; Xu, C.; Bi, G. Q.; Zhuang, X., Super-resolution fluorescence imaging of organelles in 
live cells with photoswitchable membrane probes. Proc. Natl. Acad. Sci. U.S.A. 2012, 
109 (35), 13978-13983. 
22. Liu, T.; Hannafon, B.; Gill, L.; Kelly, W.; Benbrook, D., Flex-Hets differentially induce 
apoptosis in cancer over normal cells by directly targeting mitochondria. Mol. Cancer 
Ther. 2007, 6 (6), 1814-1822. 
23. Modica-Napolitano, J. S.; Aprille, J. R., Basis for the Selective Cytotoxicity of 
Rhodamine 123. Cancer Res. 1987, 47 (16), 4361-4365. 
24. Modica-Napolitano, J. S.; Koya, K.; Weisberg, E.; Brunelli, B. T.; Li, Y.; Chen, L. B., 
Selective Damage to Carcinoma Mitochondria by the Rhodacyanine MKT-077. Cancer 
Res. 1996, 56 (3), 544-550. 
25. Wadhwa, R.; Sugihara, T.; Yoshida, A.; Nomura, H.; Reddel, R. R.; Simpson, R.; 
Maruta, H.; Kaul, S. C., Selective Toxicity of MKT-077 to Cancer Cells Is Mediated by 
 64 
Its Binding to the hsp70 Family Protein mot-2 and Reactivation of p53 Function. Cancer 
Res. 2000, 60 (24), 6818-6821. 
26. Fantin, V. R.; Berardi, M. J.; Scorrano, L.; Korsmeyer, S. J.; Leder, P., A novel 
mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer cell 
2002, 2 (1), 29-42. 
27. Modica-Napolitano, J. S.; Aprille, J. R., Delocalized lipophilic cations selectively 
target the mitochondria of carcinoma cells. Adv. Drug Del. Rev. 2001, 49 (1-2), 63-70. 
28. Rin Jean, S.; Tulumello, D. V.; Wisnovsky, S. P.; Lei, E. K.; Pereira, M. P.; Kelley, S. 
O., Molecular vehicles for mitochondrial chemical biology and drug delivery. ACS 
chemical biology 2014, 9 (2), 323-333. 
29. Nicholls, D. G., The influence of respiration and ATP hydrolysis on the proton-
electrochemical gradient across the inner membrane of rat-liver mitochondria as 
determined by ion distribution. Eur. J. Biochem. 1974, 50 (1), 305-315. 
30. Chen, L. B., Mitochondrial membrane potential in living cells. Ann. Rev. Cell Biol. 
1988, 4, 155-181. 
31. Perry, S. W.; Norman, J. P.; Barbieri, J.; Brown, E. B.; Gelbard, H. A., Mitochondrial 
membrane potential probes and the proton gradient: a practical usage guide. 
Biotechniques 2011, 50 (2), 98-115. 
32. Belostotsky, I.; da Silva, S. M.; Paez, M. G.; Indig, G. L., Mitochondrial targeting for 
photochemotherapy. Can selective tumor cell killing be predicted based on n-
octanol/water distribution coefficients? Biotechnic. Histochem. 2011, 86 (5), 302-314. 
 65 
33. Whitaker, J. E.; Haugland, R. P.; Moore, P. L.; Hewitt, P. C.; Reese, M.; Haugland, 
R. P., Cascade Blue derivatives: Water soluble, reactive, Blue emission dyes evaluated 
as fluorescent labels and tracers. Anal. Biochem. 1991, 198 (1), 119-130. 
34. Sjoback, R.; Nygren, J.; Kubista, M., Absorption and Fluorescence Properties of 
Fluorescein. Spectrochim. Acta A 1995, 51 (6), L7-L21. 
35. Feng, Y.; Zhang, N.; Jacobs, K. M.; Jiang, W.; Yang, L. V.; Li, Z.; Zhang, J.; Lu, J. 
Q.; Hu, X.-H., Polarization imaging and classification of Jurkat T and Ramos B cells 
using a flow cytometer. Cytometry Part A 2014, 85 (9), 817-826. 
36. Smith, R. A. J.; Porteous, C. M.; Gane, A. M.; Murphy, M. P., Delivery of bioactive 
molecules to mitochondria in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100 (9), 5407-
5412. 
37. Murphy, M. P., Targeting lipophilic cations to mitochondria. Biochim. Biophys. Acta 
2008, 1777 (7–8), 1028-1031. 
38. Westermann, B., Mitochondrial fusion and fission in cell life and death. Nat. Rev. 
Mol. Cell Biol. 2010, 11 (12), 872-884. 
39. Karbowski, M.; Youle, R. J., Dynamics of mitochondrial morphology in healthy cells 
and during apoptosis. Cell Death Differ. 2003, 10 (8), 870-880. 
40. Fan, X.; Hussien, R.; Brooks, G. A., H2O2-induced mitochondrial fragmentation in 
C2C12 myocytes. Free Radic. Biol. Med. 2010, 49 (11), 1646-1654. 
41. Kadenbach, B., Intrinsic and extrinsic uncoupling of oxidative phosphorylation. 
Biochim. Biophys. Acta 2003, 1604 (2), 77-94. 
42. Wallace, D. C., Mitochondria and cancer. Nat. Rev. Cancer 2012, 12 (10), 685-698. 
 66 
43. Lampidis, T. J.; Bernal, S. D.; Summerhayes, I. C.; Chen, L. B., Selective Toxicity of 
Rhodamine 123 in Carcinoma Cells in Vitro. Cancer Res. 1983, 43 (2), 716-720. 
44. Hynes, J.; Hill, R.; Papkovsky, D. B., The use of a fluorescence-based oxygen 
uptake assay in the analysis of cytotoxicity. Toxicol. In Vitro 2006, 20 (5), 785-792. 
45. Marroquin, L. D.; Hynes, J.; Dykens, J. A.; Jamieson, J. D.; Will, Y., Circumventing 
the crabtree effect: Replacing media glucose with galactose increases susceptibility of 
HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 2007, 97 (2), 539-547. 
46. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F., A specific inhibitor of 
phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
(LY294002). J. Biol. Chem. 1994, 269 (7), 5241-5248. 
47. Sena, L. A.; Chandel, N. S., Physiological roles of mitochondrial reactive oxygen 
species. Molecular cell 2012, 48 (2), 158-167. 
48. Brand, M. D.; Affourtit, C.; Esteves, T. C.; Green, K.; Lambert, A. J.; Miwa, S.; 
Pakay, J. L.; Parker, N., Mitochondrial superoxide: production, biological effects, and 
activation of uncoupling proteins. Free Radic. Biol. Med. 2004, 37 (6), 755-767. 
49. Murphy, M. P., How mitochondria produce reactive oxygen species. Biochem. J. 
2009, 417, 1-13. 
50. Muller, F., The nature and mechanism of superoxide production by the electron 
transport chain: Its relevance to aging. Journal of the American Aging Association 2000, 
23 (4), 227-253. 
51. Fleury, C.; Mignotte, B.; Vayssière, J.-L., Mitochondrial reactive oxygen species in 
cell death signaling. Biochimie 2002, 84 (2–3), 131-141. 
 67 
52. Ushio-Fukai, M.; Alexander, R. W.; Akers, M.; Yin, Q.; Fujio, Y.; Walsh, K.; 
Griendling, K. K., Reactive oxygen species mediate the activation of Akt/protein kinase 
B by angiotensin II in vascular smooth muscle cells. J. Biol. Chem. 1999, 274 (32), 
22699-22704. 
53. Siddiqui, M. A.; Ahmad, J.; Farshori, N. N.; Saquib, Q.; Jahan, S.; Kashyap, M. P.; 
Ahamed, M.; Musarrat, J.; Al-Khedhairy, A. A., Rotenone-induced oxidative stress and 
apoptosis in human liver HepG2 cells. Mol. Cell. Biochem. 2013, 384 (1-2), 59-69. 
54. Weiss, M. J.; Wong, J. R.; Ha, C. S.; Bleday, R.; Salem, R. R.; Steele, G. D., Jr.; 
Chen, L. B., Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity 
based on selective mitochondrial accumulation. Proc. Natl. Acad. Sci. U.S.A. 1987, 84 
(15), 5444-5448. 
55. Lim, S. H.; Wu, L.; Burgess, K.; Lee, H. B., New cytotoxic rosamine derivatives 
selectively accumulate in the mitochondria of cancer cells. Anticancer Drugs 2009, 20 
(6), 461-8. 
56. Fonseca, S. B.; Pereira, M. P.; Mourtada, R.; Gronda, M.; Horton, K. L.; Hurren, R.; 
Minden, M. D.; Schimmer, A. D.; Kelley, S. O., Rerouting chlorambucil to mitochondria 
combats drug deactivation and resistance in cancer cells. Chem. Biol. 2011, 18 (4), 
445-453. 
57. Horton, K. L.; Stewart, K. M.; Fonseca, S. B.; Guo, Q.; Kelley, S. O., Mitochondria-
penetrating peptides. Chem. Biol. 2008, 15 (4), 375-382. 
58. Modica-Napolitano, J. S.; Aprille, J. R., Delocalized lipophilic cations selectively 
target the mitochondria of carcinoma cells. Adv. Drug Del. Rev. 2001, 49 (1–2), 63-70. 
 68 
59. Smith, R. A.; Hartley, R. C.; Murphy, M. P., Mitochondria-targeted small molecule 
therapeutics and probes. Antioxid. Redox Sign. 2011, 15 (12), 3021-3038. 
60. Wang, F.; Ogasawara, M. A.; Huang, P., Small mitochondria-targeting molecules as 
anti-cancer agents. Mol. Asp. Med. 2010, 31 (1), 75-92. 
61. Anderson, W. M.; Patheja, H. S.; Delinck, D. L.; Baldwin, W. W.; Smiley, S. T.; 
Chen, L. B., Inhibition of bovine heart mitochondrial and Paracoccus denitrificans 
NADH----ubiquinone reductase by dequalinium chloride and three structurally related 
quinolinium compounds. Biochem Int. 1989, 19 (4), 673-685. 
62. Fantin, V. R.; Leder, P., Mitochondriotoxic compounds for cancer therapy. 
Oncogene 2006, 25 (34), 4787-4797. 
63. Loffler, M.; Jockel, J.; Schuster, G.; Becker, C., Dihydroorotate-ubiquinone 
oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol. 
Cell. Biochem. 1997, 174 (1-2), 125-129. 
64. Raveh, A.; Delekta, P. C.; Dobry, C. J.; Peng, W.; Schultz, P. J.; Blakely, P. K.; Tai, 
A. W.; Matainaho, T.; Irani, D. N.; Sherman, D. H.; Miller, D. J., Discovery of potent 
broad spectrum antivirals derived from marine actinobacteria. PLoS One 2013, 8 (12), 
e82318. 
65. Sun, Q.; Wu, R.; Cai, S.; Lin, Y.; Sellers, L.; Sakamoto, K.; He, B.; Peterson, B. R., 
Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV. 
J. Med. Chem. 2011, 54 (5), 1126-1139. 
66. Sun, W.-C.; Gee, K. R.; Haugland, R. P., Synthesis of novel fluorinated coumarins: 







Synthesis of Fluorophores that Target Small Molecules to the Endoplasmic 
Reticulum of Living Mammalian Cells 
 
3.1 Introduction 
The endoplasmic reticulum (ER), an organelle found in all eukaryotic cells, 
generally contains at least half of all the membranes found in animal cells. The ER is 
spread throughout the cytosol to define a network of tubes and sacs that enclose a 
single internal space termed the lumen. Numerous processes essential for cellular 
maintenance and survival occur on and in the ER. The external surface of the ER 
captures ribosomes involved in translation of membrane-bound and secreted proteins, 
whereas the lumen stores intracellular calcium, regulates folding and posttranslational 
processing of proteins in the secretory pathway, and is a major site of cellular lipid 
biosynthesis.1 
Stressful conditions can cause unfolded proteins to accumulate in the ER.2 
These stressors include changes in redox status due to hypoxia, oxidants or reductants, 
glucose deprivation, altered calcium regulation, viral infection and expression of 
aberrant proteins. This triggers an unfolded protein response (UPR) in the ER that 
initiates complex signaling pathways. These pathways either promote adaptive 
responses such as upregulation of protective proteins, or cellular death through 
apoptosis or even necrosis when stress is excessive.3  Numerous pathologies are 
 71 
associated with ER stress including neurodegenerative disease, stroke, heart disease, 
diabetes, and cancer.4-7 
Because of the importance of the ER in disease, modulators of targets in this 
organelle are of substantial interest as potential therapeutics and probes. Small 
molecules that promote ER stress and trigger apoptosis have potential as anticancer 
agents, and may exhibit a unique cytotoxic mechanism of action that avoids mutagenic 
damage to DNA.4 Small molecules known to induce ER stress include tunicamycin,8-9 
brefeldin A,10-12 versipelostatin,13-15 bortezomib (Velcade),16-17 and eeyarestatin I.18-24 
Some small molecules accumulate selectively in the ER. These compounds are 
generally amphipathic and moderately lipophilic.25 Structures of highly fluorescent26 
molecular probes that allow selective imaging of this organelle by microscopy, including 
ER Tracker Blue-White DPX27 and BODIPY Nile Red,28 are shown in Figure 3.1. The 
selectivity of these compounds for the ER has been proposed25, 29 to involve association 
with lipids comprising the cholesterol-poor ER membranes.30 Despite the ER membrane 
having a surface area comparable to or greater than the plasma membrane, only 0.5-
1% of the total cellular cholesterol is contained in the ER verses the 30-40% of the total 
cellular cholesterol contained in the plasma membrane.31-32 Cholesterol content of other 
organelles (Golgi, mitochondria, lysosomes, etc) is intermediate between these two 
extremes.33 Other fluorescent ER probes, such as ER Tracker Green and ER Tracker 
Red (Figure 3.1), link the BODIPY fluorophore to glibenclamide. This compound binds 
to sulphonylurea receptors of ATP-sensitive potassium channels that are abundant on 
the cytosolic face of ER membranes.34 However, binding to these channels can alter ER 
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function by perturbing calcium homeostasis,35 and probes of the ER that do not bind 
potassium channels may be advantageous for imaging and delivery applications. 
 
 
Figure 3.1. Structures of known fluorescent probes of the ER (top), the classical 
fluorophores rhodamine 110 and rhodol (bottom left), and novel fluorinated hydrophobic 
rhodols (bottom right). 
 
Here, we report the synthesis of a new class of fluorinated hydrophobic rhodols 
(Figure 3.1). These highly fluorescent compounds are structurally related to the 
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fluorophores rhodol and rhodamine 110 (Figure 3.1). However, these rhodol analogues 
are distinct from other rhodols and rhodamines in that they selectively accumulate in the 
ER of living mammalian cells. To explore the utility of this unique biological activity, we 
coupled a fluorinated hydrophobic rhodol to (2E)-3-(5-nitro-2-furanyl)-2-propenal. This 
nitrofuran, present as the hydrazone derivative in the ER-targeted agent eeyarestatin I, 
inhibits the protein p9722 to block the ubiquitin-proteasome system (UPS). We 
demonstrate that an analogous ER-targeted rhodol-nitrofuran enhances cytotoxicity in 
HeLa cells compared to an nitrofuran derivative that is not targeted to the ER, and 
blocks the UPS, offering a specific mechanism of cytotoxicity against a cancer cell line. 
These compounds represent a novel fluorescent chemotype for the targeting of 
pathways that are specifically localized in the ER of living mammalian cells. 
 
3.2 Synthesis of Hydrophobic Fluorinated Rhodols 
Our laboratory recently reported improved methodology36-37 for the synthesis of 
2,7-difluoro-3,6-dihydroxyxanthene-9-one (1, Figure 3.2). This xanthone building block 
was used to prepare multigram quantities of the fluorinated fluorophore Pennsylvania 
Green (2)38-39 via a previously published method.37, 39 At neutral pH, Pennsylvania 
Green (2) is anionic (bearing a delocalized phenolate, pKa = 4.8), hydrophobic 
(cLogDpH7.4 = 2.5), and cell-permeable.38 To investigate the properties of derivatives that 
replace the hydroxyl group of 2 with secondary amines, we transformed 2 into 
iodoarene 3, followed by conversion to rhodol 4 under Buchwald-Hartwig cross-coupling 
conditions with microwave irradiation (Figure 3.2). This approach is similar to methods 
used to prepare other rhodols40 and rhodamines.41 Consistent with other reports,42-43 
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microwave irradiation was found to accelerate the reaction compared with conventional 
heating, and the iodoarene 3 proved to be a more stable intermediate compared to the 
corresponding phenolic triflate ester. Rhodol 4 represents a unique fluorinated 
hydrophobic (cLogP = 3.9) analogue of other previously reported40, 44-48 rhodol 
fluorophores that are typically negatively charged at physiological pH (typical cLogP < 1, 
see structures of Figure 3.3D). 
 
 
Figure 3.2. Synthesis of the fluorinated rhodol 4. 
 
3.3 Photophysical Properties of Hydrophobic Fluorinated Rhodols 
Rhodols are generally fluorescent in a wide variety of solvents.40, 44 To examine 
the photophysical properties of rhodol 4, we obtained absorbance and fluorescence 
emission spectra of this compound in PBS, ethanol, and octanol. We further measured 
the quantum yield of 4 in PBS and ethanol, relative49 to rhodamine 6G, and the 
extinction coefficient in EtOH and PBS (Figure 3.3). As shown in Figure 3.3, 4 exhibited 
spectral properties (Abs. λmax = 512 nm; Ex. λmax = 532 nm, ε = 73,500 M-1 cm-1, Φ 
(EtOH) = 0.84) between fluorescein (Abs. λmax = 490 nm, Em. λmax = 517 nm, ε = 
76,900–87,600 M-1 cm-1, Φ (aqueous, pH > 8) = 0.92-0.95)50-52 and rhodamine 6G (Abs. 
λmax = 530 nm, Em. λmax = 552 nm, ε = 116,000 M-1 cm-1, Φ (EtOH) = 0.95).52-53 These 
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properties enable convenient excitation of 4 with either the 488 nm or 532 nm laser lines 
commonly found on many confocal laser scanning microscopes. Because this 
compound is substantially brighter than structurally similar rhodols bearing tertiary 
amines,48 and based on other published studies of rhodols bearing secondary 
amines,45, 54 the secondary amine substituent of 4 undoubtedly contributes to its high 
quantum yield (see comparison of Figure 3.3D). 
 
Figure 3.3. Photophysical properties of rhodol 4. Panel A: Absorbance (Abs.) and 
normalized fluorescence emission (Em.) spectra in aqueous buffer (PBS, phosphate 
buffered saline, pH 7.4), absolute ethanol, and n-octanol. Absorbance spectra were 
acquired at a concentration of 10 µM. Emission spectra, acquired at a concentration of 
10 nM, were obtained by excitation at 500 nm. Fluorescence emission intensities were 
normalized to 100% of Abs. lmax. Panel B: Determination of quantum yields of 4 in 
ethanol and PBS (pH 7.4, 0.5% Triton X-100) relative to rhodamine 6G in ethanol. Panel 
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C: Data and linear regression used to determine molar extinction coefficients of 4 in 
ethanol and PBS (pH 7.4) containing Triton X-100 (0.5%). Panel D: Structures of 
previously reported55 rhodamines containing diethylamine and monoethylamine 
sidechains. The differences in quantum yield (Φ) are shown. cLogP values were 
calculated for the ionized form using ChemAxon Marvin Sketch 6.2.  
 
3.4 Confocal Laser Scanning Microscopy of HeLa Cells Treated with Hydrophobic 
Fluorinated Rhodols 
To examine the subcellular distribution of rhodol 4, human HeLa cervical 
carcinoma cells were treated this compound and imaged by confocal laser scanning 
microscopy. As shown in Figure 3.4, these experiments revealed accumulation of 4 in 
distinct tubular structures. These structures were identified as the ER by colocalization 
with the spectrally orthogonal organelle marker ER Tracker Blue-White (Figure 3.4). 
Although the mechanism of the selectivity of fluorophores such as ER-Tracker Blue-
White or 4 for the ER is not completely understood, QSAR25, 56 and microscopy29 
studies of related probes suggest that these types of hydrophobic amphipathic 






Figure 3.4. Confocal laser scanning and DIC micrographs of living HeLa cells treated 
with ER-tracker Blue-White DPX (0.1 µM, 0.5 h) and 4 (0.5 µM, 0.5 h). The fluorescence 
emission of ER-tracker Blue-White DPX can be observed in the upper left panel and the 
fluorescence emission of the spectrally orthogonal 4 can be observed in the upper right 
panel. Colocalization of these two fluorophores is shown in yellow in the lower left 










Figure 3.5. Panel A: Structure of eeyarestatin I. Panel B: Synthesis of the nitrofuran 
control 9 and the fluorinated rhodol-nitrofuran 10. 
!
!
3.5 Targeting the ERAD pathway with Fluorinated Hydrophobic Rhodols 
Eeyarestatin I (Figure 3.5) exhibits cytotoxic activity by inhibiting the protein p97 
in the ER. This agent was initially identified in a high throughput screen for compounds 
that interfere with the turnover of a MHC heavy chain protein fused to green fluorescent 
protein, a process that involves degradation of this protein by the proteasome.18 
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However, eeyarestatin I does not directly inhibit the proteasome, but instead blocks the 
upstream p97 complex of ER membranes.19, 22 Eeyarestatin I was shown to directly 
interact with p97 through surface plasma resonance (SPR) studies, although the 
specific binding site on p97 remains unclear.22 This complex translocates misfolded 
polypeptides from the ER to the cytosol for eventual degradation by the proteasome. 
Although its mechanism of action is not completely understood, eeyarestatin I is known 
to inhibit the deubiquitinating activity of p97-associated enzyme ataxin-3 (atx3),19 block 
Sec61-mediated protein translocation at the ER,21 affect vesicular transport,23 activate 
of the UPR caused by accumulation of ubiquitinated poylpeptides,58 and trigger ER-
stress due to a build-up of misfolded proteins, thereby inducing apoptosis in some 
cancer cell lines.20, 59 Previous structure-activity relationship studies of eeyarestatin I 
using SPR22 demonstrated that the 5-nitrofuran-2-acrylaldehyde hydrazone functions as 
a warhead that physically interacts with the p97 complex, whereas the aryl urea moiety 
principally localizes this nitrofuran warhead to ER membranes to gain selectivity for ER-
membrane-bound p97 over the cytosolic form of this protein. (2E)-3-(5-nitro-2-furanyl)-
2-propenal and related compounds are electrophilic can be further bioactivated to form 
mutagenic reactive species.56,57 Consequently, targeting of this group to the ER could 
potentially reduce its mutagenicity.  
To investigate whether fluorinated hydrophobic rhodols might provide a platform 
for delivery of stress-inducing cargo to the ER, we designed compound 10 (Figure 3.5). 
This compound links the ER-targeting rhodol to the (2E)-3-(5-nitro-2-furanyl)-2-propenal 
hydrazone warhead found in eeyarestatin I. The nitrofuran derivative 9 was designed as 
an untargeted control. As shown in Figure 3.5, ester 5 was synthesized from iodoarene 
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3 and γ-aminobutyric acid t-butyl ester using Buchwald-Hartwig cross-coupling. This 
resulting ester was deprotected and converted to hydrazide 6. Hydrazides 6 and 8 were 
subsequently condensed with aldehyde 7 to afford the nitrofuran derivatives 9 and 10. 
To ensure that the ER-targeting ability of the rhodol was unaffected by attachment of 
the warhead, HeLa cells were treated with 10 and ER-Tracker Blue-White and analyzed 
by confocal laser scanning microscopy. Cellular imaging demonstrated that addition of 
the nitrofuran moiety did not affect localization of the rhodol to the ER (Figure 3.6). To 
compare the cytotoxicities of eeyarestatin I, 6, 9 and 10, HeLa cells were treated with 
these compounds for 48 h. The rhodol-nitrofuran 10 (IC50= 2.7 µM) and eeyarestatin I 
(IC50 = 2.0 µM) were found to be similar in potency, indicating that the ER-targeting 
motifs of both of these compounds are effective at delivering the nitrofuran warhead to 
this organelle (Figure 3.7). As controls, hydrazide 6, lacking the cytotoxic warhead, 
showed no appreciable toxicity (IC50 > 50 µM), whereas the nitrofuran warhead 9 alone 





Figure 3.6. Confocal laser scanning and DIC micrographs of living HeLa cells treated 
with 10 (0.5 µM, 0.5 h) and ER-tracker Blue-White (0.1 µM, 0.5 h). The fluorescence 
emission of ER-tracker Blue-White DPX can be observed in the upper left panel, the 
fluorescence emission of 10 can be observed in the upper right panel. Colocalization of 




Figure 3.7. Cytotoxicity of eeyarestatin I, the ER-targeted rhodol-nitrofuran 10, the 
nontargeted nitrofuran 9, and the rhodol hydrazide 6 towards HeLa cells after 48 h in 
culture. Cellular viability was measured by flow cytometry using P.I. exclusion and light-
scattering. 
 
Eeyarestatin I blocks the UPS by inhibiting the p97 protein on ER membranes. 
This protein is required for maturation of the transcription factor Nrf1, which activates 
genes that encode subunits of the proteasome.60 To characterize inhibitors of the UPS, 
cells are typically transfected with green or yellow fluorescent proteins fused to a 
ubiquitin degradation signal.61-62  These proteins function as reporters because the 
fused ubiquitin results in trafficking to the proteasome, where they are rapidly 
degraded.63 Pharmacological inhibitors of the proteasome such as MG132,61, 64 
bortezomib,65 and epoxomicin62 have been shown to prevent degradation of these 
reporter proteins and restore cellular fluorescence. Similarly, inhibition of the upstream 
ER-associated p97 protein by DBeQ,66 eeyarestatin I,66  and ML240/ML24167 prevents 
their downstream degradation, thereby allowing their accumulation to observable levels.  
To examine whether rhodol 10 inhibits the same pathway targeted by 
eeyarestatin I, we constructed a new fluorescent reporter. This reporter comprises a 
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G76V mutant of ubiquitin (UbG76V)61, 68 fused to the cyan fluorescent protein cerulean. 
The cyan fluorescence of this protein was chosen to provide spectral orthogonality to 
the yellow fluorescent rhodols. To validate this reporter, HeLa cells were transiently 
transfected with cerulean as a positive control (Figure 3.8, panel A) and UbG76V-
cerulean as a reporter of UPS function (Figure 5, panels B-E). In the absence of 
inhibitors, cells transfected with the UbG76V-cerulean reporter showed no appreciable 
cellular fluorescence, consistent with rapid degradation of this protein by the 
proteasome (Figure 3.8). However, when these cells were treated for 12 h with the 
proteasome inhibitor bortezomib or the p97 inhibitor eeyarestatin I, the transfected cells 
became highly cyan fluorescent. Correspondingly, when treated with rhodol 10, 
cerulean was highly expressed at levels essentially identical to cells treated with 
eeyarestatin I, demonstrating that 10 specifically inhibits the UPS. Importantly, when the 
untargeted nitrofuran control 9 was examined (Figure 3.8, Panel F), no appreciable 
fluorescence was observed suggesting the targeting motif of 10 is critical for activity. 
Based on its selective localization in the ER, and prior studies of the same warhead in 
eeyarestatin I, the effects of 10 on cellular proliferation and the UPS likely result from 




Figure 3.8. Confocal laser scanning and differential interference contrast (DIC) 
micrographs of living HeLa cells transiently transfected with the cyan fluorescent protein 
cerulean (panel A) as a positive control or UbG76V-cerulean (panels B-E) as a reporter of 
inhibition of the ubiquitin-proteasome system. Inhibition of the UPS prevents 
degradation of UbG76V-cerulean, resulting in cells expressing this cyan fluorescent 
protein. The fluorescence of cerulean can be observed in the cyan (left) channel and the 
spectrally orthogonal rhodol 10 can be observed in the yellow (middle) channel. The 
cyan fluorescence was generated by excitation with a 405 nm laser, and the yellow 
fluorescence was generated by excitation with a 532 nm laser. Cells were treated with 
vehicle (DMSO, 0.1%, panel B), bortezomib (100 nM), Eer1 (5 µM), 10 (5 µM), or 9 (5 




The results presented here demonstrate that a fluorinated hydrophobic rhodol 
can be used to selectively deliver biologically active cargo to the ER. When the cargo is 
a 5-nitrofuran warhead, delivery to the ER resulted in inhibition of the UPR, with 
concomitant effects on cellular proliferation. Given the widespread interest in targeting 
of ER-associated proteins for potential treatment of cancer4, 69 neurodegeneration,70 and 
other diseases,71 these compounds may provide useful tools for the delivery of agents 
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3.7  Experimental Section 
3.7.1 General. 1H NMR and 13C NMR spectra were acquired on Bruker DRX-400 or 
Avance AVIII 500 MHz instruments. Chemical shifts (d) are reported in ppm referenced 
to CDCl3. 1H coupling constants (JHH, Hz) are reported as follows: chemical shift, 
multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dt = 
doublet of triplets, dt = doublet of quartets, dd = doublet of doublets), coupling constant, 
and integration. 13C coupling constants (JCF, Hz) are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, dd= doublet of doublet). Consistent with previously 
published studies of related compounds,72-73 E/Z rotamers of hydrazones 9 and 10 were 
observed in 1H and 13C NMR spectra. Peaks from the major rotamer are reported in the 
characterization data. Infrared spectra (IR) were recorded with a Perkin-Elmer Spectrum 
100 FT-IR spectrophotometer. Absorbance spectra were obtained using semimicro (1.5 
mL) methacrylate cuvettes on an Aligent 8452A diode array spectrometer. Fluorescence 
spectra were acquired using semimicro (1.5 mL) methacrylate cuvettes and a Perkin-
Elmer LS55 Fluorescence Spectrometer (10 nm excitation slit width). High Resolution 
mass spectra were obtained at the Mass Spectrometry Laboratory at the University of 
Kansas on a Micromass LCT Premier. Elemental analysis was performed by Midwest 
MicroLabs. Thin layer chromatography (TLC) was performed using EMD aluminum-
backed (0.20 mm) silica plates (60 F-254), and flash chromatography used ICN silica 
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gel (200-400 mesh). TLC plates were visualized by UV lamp or staining with ceric 
sulfate/molybdic acid. All non-aqueous reactions were carried out using flame- or oven-
dried glassware under an atmosphere of dry argon or nitrogen. Tetrahydrofuran (THF), 
dichloromethane (CH2Cl2), N,N-dimethylformamide (DMF), methanol (MeOH), ether 
(Et2O), and triethylamine (TEA) were purified via filtration through two columns of 
activated basic alumina under an atmosphere of Ar using a solvent purification system 
from Pure Process Technology (GlassContour). Other commercial reagents were used 
as received unless otherwise noted. Eeyarestatin I was obtained from Tocris or Cayman 
Chemicals. Measurements for molar extinction coefficients and relative quantum yield 
were preformed using a SUPRASIL macro/semi micro quartz cuvette (PerkinElmer, 
B0631132). Molar extinction coefficients (ε) were calculated from Beer’s Law plots of 
absorbance lmax versus concentration as shown in Figure S1. Linear least squares fitting 
of the data (including a zero intercept) was used to determine the slope (corresponding 
to ε). Values (M-1 cm-1) were calculated as follows: Absorbance = ε [concentration (M)] L, 
where L = 1 cm. Relative quantum yields (Φ) in ethanol were determined by the method 
of Williams.49 Fluorophores were excited at 488 nm and the integrated fluorescence 
emission (500 nm to 800 nm) was quantified (concentrations of 3.3 nM to 16.7 nM). 
Rhodamine 6G (Φ = 0.95 in ethanol) provided the standard.74-76 The integrated 
fluorescence emission at a given concentration was plotted against the maximum 
absorbance of the sample at that concentration determined by extrapolation based on 
absorbance measurements at higher concentrations. Linear least squares fitting of the 
data (including a zero intercept) was used to calculate the slope, which is proportional to 
the quantum yield. Quantum yields were calculated as follows: Φx = 
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Φst(Gradx/Gradst)(η2x/η2st), where Φst represents the quantum yield of the standard, Φx 
represents the quantum yield of the unknown, Grad is the slope of the best linear fit, 
and η is the refractive index of the solvent used.  
 
3.7.2 Cell Culture The HeLa (CCL-2) cell line was obtained from ATCC. Dulbecco’s 
Modified Eagle Medium (DMEM, Sigma D5796) was supplemented with FBS (10%, 
Sigma F0926), penicillin (100 units/L), and streptomycin (100 µg/L, Sigma P4333).  
 
3.7.3 Plasmids The plasmid encoding UbG76V-YFP was a gift from Nico Dantuma 
(Addgene plasmid # 11949).62 The plasmid encoding cerulean-N1 was a gift from 
Michael Davidson & Dave Piston (Addgene plasmid # 54742). The open-reading frame 
encoding YFP in UbG76V-YFP was replaced with the open-reading frame of cerulean-N1 
by digestion of both vectors with NotI and AgeI and subcloning to afford UbG76V-cerulean 
in the EGFP-N1 (Clontech) vector backbone bearing a kanamycin bacterial resistance 
marker. 
 
3.7.4 Cellular Toxicity: HeLa cells were seeded on a 96-well plate in complete DMEM 
at 4000 cells / 100 µL / well 24 h prior to treatments. All compounds were serial diluted 
in DMSO and added to media to achieve a 1:1000 dilution factor (0.1% DMSO in each 
well). The original media was removed from all wells by aspiration and replaced with 
treatment media (150 µL) at the concentrations indicated. Plates were incubated for 48 
h at 37 °C and cells were analyzed in triplicate. Following this incubation period, the 
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media was aspirated and wells were washed with PBS (phosphate-buffered saline, pH 
7.4). Wells were further treated with trypsin EDTA solution (50 µL) at 37 °C for 5 min 
followed by complete DMEM (100 µL) containing propidium iodide (P.I., 4.5 µM). The 
total cell count for each well was determined by flow cytometry (Accuri C6 instrument) 
using light scattering and P.I.-negative gates to identify populations of live cells. Counts 
of viable cells for each treatment were used to generate dose-response curves that 
were fitted by non-linear regression (GraphPad Prism 6 software) to determine IC50 
values. 
 
3.7.5 Confocal Microscopy of Cells Treated with ER-Tracker Blue-White DPX: Prior 
to treatment with compounds, HeLa cells in DMEM were added to an 8-well cover glass 
slide (Idibi µ-Slide, 200 µL, 20,000 cells/well) and allowed to proliferate for 24 h. 
Compounds in DMSO stock solutions were diluted 1000-fold with complete media prior 
to addition to cells. Cells were imaged using a Leica SPE2 confocal laser-scanning 
microscope fitted with a 63X objective. Cells were treated (15 min, 37 °C) with ER-
Tracker Blue-White DPX (500 nM) and rhodol fluorophores (500 nM). Cells were 
imaged without any additional washing steps. ER-Tracker Blue-White DPX was excited 
with a 405 nm laser and emitted photons were collected from 415 nm to 500 nm. 
Hydrophobic fluorinated rhodols were excited with a 488 nm laser and emitted photons 
were collected from 500 nm to 600 nm.  
 
3.7.6 Ubiquitin Degradation Assays by Confocal Microscopy: HeLa cells in DMEM 
were added to an 8-well cover glass slide (Idibi µ-Slide, 200 µL, 10,000 cells/well) and 
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allowed to attach for 12 h. Cells were treated with X-tremeGene HP (Roche) according 
to the protocol of the manufacturer (30 µL of complex solution/well) for transient 
transfection of the plasmid UbG76V-cerulean as a reporter for protein degradation. 
Cerulean-N1 provided a positive control, and adjacent untransfected cells provided a 
negative control, for these experiments. After 24 h, the media was replaced with DMEM 
containing either vehicle or inhibitors (DMSO final concentration = 0.1%). Wells were 
incubated (12 hours, 37 °C) followed by washing with DMEM. Cells were imaged using 
a Leica SPE2 confocal laser-scanning microscope fitted with a 40X objective. 
Expressed cerulean was visualized by excitation with a 405 nm laser with emitted 
photons collected between 425 nm to 500 nm. Rhodol fluorphores were excited a 532 
nm laser with emitted photons collected between 550 nm to 700 nm. Figure 5 shows 
representative fields of cells for each treatment.   
 
3.7.7 Synthetic Procedures and Compound Characterization Data 
 
2,7-Difluoro-6-iodo-9-(o-tolyl)-3H-xanthen-3-one (3). To a dry, argon-flushed round-
bottomed flask was added Pennsylvania Green37, 39 (2, 1000 mg, 2.95 mmol, 1.0 equiv) 
and N,N-bis(trifluoromethylsulfonyl)aniline. Anhydrous 1,4-dioxane (Sigma) was added 
(20 mL), followed by triethylamine (490 µL, 3.55 mmol, 1.2 eq). The flask was heated 
under Ar to 60 °C for 1 h. Conversion to the intermediate triflate was observed by TLC 
(eluent: MeOH/CH2Cl2, 1:20). The flask was removed from the oil bath and lithium 
iodide (1.184 g, 8.99 mmol, 3 eq) and a reflux condenser were added. The solution was 
refluxed for 4 h. The flask was cooled to room temperature (22 °C), aqueous NaOH (2 N, 
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5 mL) was added, and the solution was stirred 1 h. Water (60 mL) was added, giving 
rise to a product slurry that was stirred for 1 h. This slurry was chilled to 4 °C, filtered, 
and the product cake washed with cold water (3 x 20 mL) to give 7 containing residual 
1,4-dioxane. This product cake was treated with diethyl ether (5 mL), stirred vigorously 
for 1 min, and hexanes (5 mL) were added. The resulting slurry was filtered and the 
product cake extensively dried under high vacuum to provide 7 (1.123 g, 85%) as an 
orange solid. 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 5.1 Hz, 1H), 7.52 (td, J = 7.6, 1.4 
Hz, 1H), 7.42 (dd, J = 14.9, 7.4 Hz, 2H), 7.14 (dd, J = 7.6, 1.4 Hz, 1H), 6.69 (d, J = 7.8 
Hz, 1H), 6.65 – 6.52 (m, 2H), 2.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 176.75 (d, J = 
21.1 Hz), 159.21, 157.80, 157.27, 156.79 (d, J = 1.8 Hz), 155.65, 147.94, 136.01 , 
131.24 , 131.08 , 130.28 , 128.89 , 127.87 , 127.85 , 126.66 , 121.28 (dd, J = 48.3, 8.1 
Hz), 110.94 (dd, J = 308.0, 27.7 Hz), 107.02 , 87.75 (d, J = 30.5 Hz), 19.64 . IR nmax: 
3030, 1647, 1620, 1561, 1477, 1407, 1362, 1165, 1010, 751. HRMS (ESI) for 
C20H11F2IO2 (M+H+): calcd 448.9845, Found: 448.9855. 
 
2,7-Difluoro-6-((2-methoxyethyl)amino)-9-(o-tolyl)-3H-xanthen-3-one (4). An oven-
dried microwave vial (10 mL) was charged with 3 (100 mg, 0.22 mmol, 1 eq), 2-
methoxyethylamine (0.34 mmol, 1.5 eq), Pd(OAc)2 (5 mg, 0.02 mmol, 0.1 eq), xantphos 
(19 mg, 0.03 mmol, 0.15 equiv) and Cs2CO3 (219 mg, 0.42 mmol, 2 eq). The vial was 
slowly flushed with argon after which anhydrous, degassed toluene (5 mL) was added. 
The vial was sealed and heated to 120 °C in a microwave reactor for 1 h. The reaction 
tube was cooled to room temperature and diluted with CH2Cl2 (25 mL). Water (15 mL) 
was added, and the organic layer was separated. The aqueous portion was extracted (2 
 91 
x 15 mL) with CH2Cl2 and the organic layers combined and dried over anhydrous 
Na2SO4. The organic solvents were removed under reduced pressure, and the crude 
product was purified by silica gel column chromatography (eluent: CH2Cl2 to 
MeOH/CH2Cl2, 1:20) to afford 4 as a red solid (93 mg, 78% yield). 1H NMR (500 MHz, 
CDCl3) δ 7.47 (td, J = 7.6, 1.4 Hz, 1H), 7.45 – 7.34 (m, 2H), 7.13 (dd, J = 7.6, 1.5 Hz, 
1H), 6.73 (d, J = 7.0 Hz, 1H), 6.68 – 6.56 (m, 3H), 5.19 (q, J = 5.0 Hz, 1H), 3.69 (dd, J = 
5.6, 4.6 Hz, 2H), 3.47 (q, J = 5.2 Hz, 3H), 3.42 (s, 3H), 2.06 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 175.58 (d, J = 19.9 Hz), 157.44 (d, J = 263.7 Hz), 156.33 (d, J = 262.5 Hz), 
155.29, 151.84, 150.73 (d, J = 12.0 Hz), 149.47, 147.55, 142.75 (d, J = 14.4 Hz), 
135.90, 132.34, 130.76, 129.75, 128.81, 126.28, 112.66 (dd, J = 652.32, 8.4 Hz), 
111.26 (d, J = 21.5 Hz), 109.93 (d, J = 22.2 Hz), 106.24 (d, J = 5.4 Hz), 97.35 (d, J = 3.5 
Hz), 70.01, 59.03, 42.83, 19.57. IR nmax: 3279, 2933, 1729, 1655, 1613, 1597, 1543, 
1501, 1485, 1452, 1366, 1301, 1178, 1104, 751. HRMS (ESI) for C23H19F2NO3 (M+H+): 
calcd 396.1406, Found: 396.1390. 
 
tert-Butyl 4-((2,7-difluoro-3-oxo-9-(o-tolyl)-3H-xanthen-6-yl)amino)butanoate (5). 
An oven-dried microwave vial (10 mL) was charged with 3 (100 mg, 0.22 mmol, 1 eq), 
γ-aminobutyric acid t-butyl ester hydrochloride (0.34 mmol, 1.5 eq), Pd(OAc)2 (5 mg, 
0.02 mmol, 0.1 eq), xantphos (19 mg, 0.03 mmol, 0.15 equiv) and Cs2CO3 (329 mg, 
0.63 mmol, 3 eq). The vial was slowly flushed with argon after which anhydrous, 
degassed toluene (5 mL) was added. The vial was sealed and heated to 120 °C in a 
microwave reactor for 1 h. The reaction tube was cooled to room temperature and 
diluted with CH2Cl2 (25 mL). Water (15 mL) was added and the organic layer was 
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separated. The aqueous portion was extracted (2 x 15 mL) with CH2Cl2, and the organic 
layers were combined and dried over anhydrous Na2SO4. The organic solvents were 
removed under reduced pressure, and the crude product was purified by silica gel 
column chromatography (eluent: CH2Cl2 to MeOH:CH2Cl2, 1:20) to provide 5 as a red 
solid (99 mg, 93%). 1H NMR (500 MHz, CDCl3) δ 7.40 (td, J = 7.6, 1.2 Hz, 1H), 7.36 – 
7.28 (m, 2H), 7.06 (d, J = 7.4 Hz, 1H), 6.66 (d, J = 7.1 Hz, 1H), 6.59 – 6.47 (m, 3H), 
5.23 – 5.18 (1H), 3.30 (q, J = 6.7 Hz, 2H), 2.34 (t, J = 6.8 Hz, 2H), 2.03 – 1.90 (m, 2H), 
1.99 (s, 3H), 1.40 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 172.58, 175.53 (d, J = 19.9 
Hz), 157.41, 156.32 (d, J = 262.2 Hz), 151.99, 150.79 (d, J = 8.6 Hz), 149.40, 147.48, 
142.84 (d, J = 14.3 Hz), 135.89, 132.36, 130.75, 129.73, 128.80, 126.27, 112.55 (dd, J 
= 666.38, 8.33 Hz), 110.58 (dd, J = 155.58, 21.49 Hz), 106.22 (d, J = 5.4 Hz), 97.02 (d, 
J = 3.4 Hz), 81.15, 42.93, 32.88, 28.09, 23.73, 19.56. IR nmax: 3223, 2927, 1725, 1649, 
1609, 1543, 1483, 1361, 1303, 1146, 1050, 835, 756. HRMS (ESI) for C28H27F2NO4 
(M+H+): calcd 480.1981, Found: 480.1963. 
 
4-((2,7-Difluoro-3-oxo-9-(o-tolyl)-3H-xanthen-6-yl)amino)butanehydrazide (6). To a 
dry flask containing 5 (73 mg, 0.15 mmol), was added absolute ethanol (1.5 mL). 
Catalytic sulfuric acid (1 drop) was added to the homogeneous solution, and the flask 
was refluxed overnight (16 h). The flask was cooled to room temperature and the 
excess ethanol removed under reduced pressure. The crude reaction mixture was 
passed through a plug of silica with MeOH;CH2Cl2 (1:20) as the eluent. The resulting 
solution was concentrated under reduced pressure and dried under high vacuum to give 
the corresponding ethyl ester (68 mg, 99%). HRMS (ESI) for C26H23F2NO4 (M+H+): 
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calcd 452.1668, Found: 452.1686. This product carried on to the subsequent step 
without further purification. To a dry flask containing the intermediate ethyl ester (62 mg, 
0.14 mmol, 1 eq), absolute ethanol (0.5 mL) was added. Hydrazine monohydrate (41 
mg, 0.83 mmol, 6 eq) was added to the solution and the flask sealed under nitrogen. 
The reaction was stirred overnight (16 h) at which point complete conversion of the 
ester to the hydrazide was observed by TLC (eluent: MeOH/CH2Cl2, 1:9). The product 
was purified by silica chromatography, eluting with MeOH/CH2Cl2 (1:9), to afford 
compound 6 as a dark red solid (46 mg, 0.11 mmol, 77%). 1H NMR (400 MHz, CDCl3) δ 
7.49 – 7.40 (m, 1H), 7.40 – 7.32 (m, 2H), 7.08 (d, J = 7.4 Hz, 1H), 6.70 (d, J = 7.0 Hz, 
1H), 6.65 – 6.55 (m, 3H), 3.32 (t, J = 6.7 Hz, 2H), 2.31 (t, J = 6.8 Hz, 2H), 2.02 (m, J = 
7.6 Hz, 5H). 13C NMR (126 MHz, 9:1 CDCl3 / CD3OD) δ 175.21 (d, J = 19.9 Hz), 173.39, 
157.54, 156.10 (d, J = 260.4 Hz), 152.59, 148.74 (d, J= 243.18 Hz), 143.72 (d, J = 14.6 
Hz), 145.78, 132.17, 130.76, 129.84, 127.46 (d, J= 307.44 Hz), 114.44 (d, J = 8.3 Hz), 
111.10 (d, J = 21.4 Hz), 110.31 (d, J = 22.2 Hz), 110.02 (d, J = 8.4 Hz), 105.86 (d, J = 
5.2 Hz), 96.63 (d, J = 4.0 Hz), 42.69, 31.29, 23.81, 19.49. IR nmax: 3246, 2927, 1651, 
1610, 1610, 1540, 1485, 1335, 1303, 1179, 960, 751. HRMS (ESI) for C24H21F2N3O3 
(M+H+): calcd 438.1624, Found: 438.1621 
 
(2E)-3-(5-nitro-2-furanyl)-2-propenal (7). This known77 compound was prepared by 
refluxing (triphenylphosphoranylidene)acetylaldehyde  (1186 mg, 3.89 mmol, 1.1 eq) 
and 5-nitrofurylaldehyde (500 mg, 3.54 mmol, 1 eq) in dry toluene (10 mL) under argon 
for 6 h. During the course of the reaction, 1H NMR spectra of crude reaction mixtures in 
CDCl3 were used to monitor enrichment of the E isomer (10.5 ppm) over the Z isomer 
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(9.7 ppm) over time. The reaction was cooled to room temperature and diluted with 
CH2Cl2 (50 mL) and water (30 mL). The organic layer was separated and the aqueous 
layer was extracted with CH2Cl2 (2 x 50 mL). The organic layers were pooled, dried over 
anhydrous Na2SO4, and concentrated under reduced pressure. The product was 
purified by silica chromatography (eluent: EtOAc/hexane, 1:4) to give 7 as a light brown 
solid (554 mg, 93%). 1H NMR (400 MHz, CDCl3) δ 9.69 (d, J = 7.4 Hz, 1H), 7.37 (d, J = 
3.8 Hz, 1H), 7.26 (d, J = 16.0 Hz, 1H), 6.93 (d, J = 3.8 Hz, 1H), 6.80 (dd, J = 16.0, 7.4 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 191.72, 152.73, 151.86, 134.50, 130.90, 116.59, 
112.93. IR nmax: 3152, 1671, 1630, 1518, 1470, 1348, 1237, 1109, 979, 812, 737. Anal. 
Calcd for C7H5NO4: C, 50.31; H, 3.02; N, 8.38. Found C, 50.41; H, 2.96; N, 8.29. 
 
N'-((1E,2E)-3-(5-Nitrofuran-2-yl)allylidene)acetohydrazide (9). Compound 7 (50 mg, 
0.30 mmol, 1 eq) and acetic hydrazide (28.8 mg, 0.39 mmol, 1.3 eq) were charged into 
a dry flask. The solids were treated with methanol (1 mL) and stirred for 1 h, after which 
the crude product precipitated as a yellow solid. The reaction mixture is filtered and the 
crude solid product was further purified by silica gel chromatography (eluent: 
MeOH/CH2Cl2, 1:20). The product was dried under high vacuum to give 7 (35 mg, 58%) 
as a yellow solid. 1H NMR (500 MHz, 9:1 CDCl3: CD3OD) δ 7.52 (d, J = 9.5 Hz, 1H), 
7.30 (m, 1H), 7.10 – 6.98 (m, 1H), 6.64 – 6.51 (m, 2H), 2.23 (s, 3H). 13C NMR (126 
MHz, 9:1 CDCl3: CD3OD) δ 174.06, 154.26, 146.36, 143.39, 130.09, 122.67, 113.77, 
112.35, 20.20. IR nmax: 3110, 2972, 1672, 1506, 1464, 1387, 1334, 1258, 1141, 1025, 




nitrofuran-2-yl)allylidene)butanehydrazide (10). Hydrazide 6 (30 mg, 0.07 mmol) and 
aldehyde 7 (13 mg, 0.75 mmol) were placed in a dry flask. Dry methanol (0.5 mL) was 
added and reaction stirred at room temperature for 1 h. Formation of the product and 
consumption of the hydrazide, was observed by TLC (eluent: MeOH:CH2Cl2, 1:19). 
Excess methanol was removed under reduced pressure and the crude mixture purified 
with a silica column (eluent: MeOH/CH2Cl2, 1:19). The product was dried under high 
vacuum to afford 9 as a red solid (26 mg, 66%). 1H NMR (500 MHz, 9:1 CDCl3: CD3OD) 
δ 7.57 (d, J = 9.5 Hz, 1H), 7.42 (t, J = 7.5 Hz, 1H), 7.36 – 7.27 (m, 3H), 7.03 (tdd, J = 
25.5, 15.0, 9.6 Hz, 5H), 6.72 (dd, J = 11.7, 7.0 Hz, 1H), 6.59 (ddd, J = 21.7, 12.2, 6.3 
Hz, 11H), 3.36 – 3.28 (m, 14H), 2.79 (q, J = 9.0, 6.3 Hz, 1H), 2.41 (t, J = 6.7 Hz, 1H), 
2.09 – 2.02 (m, 2H), 1.97 (s, 3H). 13C NMR (126 MHz, 9:1 CDCl3: CD3OD) δ 175.42, 
175.00 (d, J = 19.0 Hz), 157.55, 157.00 (d, J = 260.9 Hz), 155.97 (d, J = 260.9 Hz), 
154.09, 152.75, 151.73, 148.80 (d, J = 247.4 Hz), 144.10, 135.69, 132.04, 130.73, 
129.85, 129.74, 128.59, 126.20, 122.96, 113.83, 112.69, 111.11 (dd, J = 89.4, 21.5 Hz), 
112.14 (dd, J = 518.3, 8.5 Hz), 110.74  (dd, J = 89.4, 21.5 Hz), 105.68 (d, J = 5.1 Hz), 
96.63, 96.43, 42.62, 31.75, 23.81, 19.40. IR nmax: 2931, 1675, 1651, 1611, 1541, 1484, 
1461, 1335, 1299, 1178, 1125, 1105, 959, 735. HRMS (ESI) for C31H25F2N4O6 (M+H+): 
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Phenotypic Screening of Fluorophores Against Zebrafish Embryos 
 
4.1 Introduction 
The zebrafish (Danio rerio) is an emerging model organism for studies of 
vertebrate biology.1-2 As phenotypic small-molecule screens gain additional 
popularity, the zebrafish offers a model well suited for high-throughput screens of 
small-molecules.3 Compared with mammals such as mice, zebrafish have 
inherent advantages to lend themselves to early in vivo screening. Adult 
zebrafish are fairly small (< 3 cm) and fertilized embryos are small enough (1 
mm) for use in 96- and 384-well plates (Figure 4.1).4 Zebrafish embryos can be 
easily produced on a large scale, and development occurs ex vivo, whereas 
mammals develop in utero and are typically cost-prohibitive to generate for large-
scale screening. Zebrafish embryos naturally develop inside the chorion, a 
protective non-cellular membrane composed of glycoproteins.5 Because the 
chorion can act as a barrier that limits compound exposure, embryos can be 
dechorionated mechanically or by proteinase treatments to allow for more 
uniform drug exposure.6 Zebrafish embryos are transparent, allowing for 
development to be monitored using optical microscopy, and induced defects 
detected in a medium- to high-throughput manner. Additionally, the zebrafish 
genome has been completely sequenced, with 70% of genes having human 
orthologs.7 These advantages make zebrafish embryos suitable for low cost in 
vivo investigation and large-scale phenotypic screening of small-molecules. 
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Figure 4.1. Panel A: A micrograph of a zebrafish zygote immediately following 
fertilization in a yolk-up orientation. The chorion surrounds the dividing cells of 
the zygote. Scale bar is 250 µm. Panel B: A micrograph of a zebrafish embryo 
without a chorion at 36 hours post fertilization (hpf). Tissues, organ systems, and 
anatomical features are becoming apparent and wild-type embryos begin 
developing strong pigmentation in the skin. Scale bar is 250 µm. Images were 




Although zebrafish embryos are well suited for fluorescence microscopy 
due to their relative transparency, the effects of small-molecule fluorophores on 
this organism has not been thoroughly investigated. More commonly, modern 
advances in genomic editing such CRISPR/Cas9 techniques are used to 
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generate fluorescent transgenic zebrafish.8-10 Transgenic fish expressing 
fluorescent proteins using tissue9 or organelle11 specific promoters have been 
successfully used to study models of disease in real time in vivo. We are 
interested in the development of small-molecule fluorescent probes for studies of 
disease models in zebrafish embryos. This approach could be advantageous for 
several reasons. First, small-molecule probes can be easily administered in food 
or directly into the system water for absorption through multiple routes. Second, 
treatment with and removal of small-molecule probes can be executed with 
temporal control to mimic dosing of other vertebrates with drugs. Small-molecule 
probes further allow researchers to tailor spectral or chemical properties to 
investigate effects on ADME-Tox (Absorption, distribution, metabolism, excretion, 
toxicology) and other parameters of synthetic compounds. 
Considering how little is understood about how small-molecule 
fluorophores interact with the zebrafish model, we sought to leverage the 
numerous small-molecule fluorescent probes developed in the Peterson 
laboratory to screen for novel phenotypes by confocal laser-scanning 
microscopy. To this end, living zebrafish embryos were treated with a number of 
probes created by members of the Peterson group and examined by looking for 
novel phenotypes. This chapter describes several “hits” from these studies and 





4.2 Hydrophobic Rhodamines for Visualization of Mitochondria in vivo 
As discussed in Chapter 2, mitochondria normally exist as an extended 
tubular network and constantly undergo fission and fusion. This dynamic process 
is critical for maintenance of normal mitochondrial function by allowing renewal of 
mitochondrial DNA and proteins.12,13 Irregularity in mitochondrial fission and 
fusion has been implicated in a number of diseases14,15 such as 
neurodegeneration, aging, and cancer. The ability to observe the morphology of 
mitochondria in model organisms is a crucial step in monitoring the progression 
of certain models of disease.16 Although a number of useful fluorescent probes 
are known to accumulate in polarized mitochondria in cell culture, to our 
knowledge the general translation of these probes to living zebrafish has not 
been previously explored. 
 Previous members of the Peterson laboratory developed the hydrophobic 
rhodamine analogues HR101 and HRB (Figure 4.2, panel A).17 These probes, 
based on the fluorophores rhodamine 101 and rhodamine B, have been used to 
observe mitochondrial fission and fusion events in the nematode model organism 
C. elegans.17 HR101 and HRB share the high lipophilicity and permanent positive 
charge that is common in other mitochondrial probes such as Rhodamine 123 
and MitoTracker Deep Red (Figure 4.2, panel A). Imaging by confocal 
microscopy revealed that all of these probes readily accumulate in the 
mitochondria of HeLa cervical carcinoma cells in culture (Figure 4.2, panel B). To 
examine their accumulation in mitochondria of zebrafish, we directly compared 
HR101 and HRB with MitoTracker Deep Red and Rhodamine 123 in zebrafish 
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embryos at 72 hours post fertilization (hpf). Interestingly, when added at the 
same concentration (1 µM), HR101 was the only probe to strongly accumulate in 
vivo under these conditions (Figure 4.2, panel C). At this relatively low 
concentration, HR101 clearly stained all the cells in the optical plane, whereas 
HRB, MitoTracker Deep Red, and Rhodamine 123 showed little to no 
fluorescence under the same conditions (Figure 4.2, panel C). We reasoned that 
because HR101 is highly absorbed and relatively uniform in its distribution 
around peripheral tissues, it may have applications as a novel counter stain for 
studies of development. To explore this idea, as shown in Figure 4.2 Panel D, we 
imaged the eye of a living dechorionated 36 hpf embryonic zebrafish with a 
confocal microscopy Z-stack, and reconstructed the image in three dimensions. 
The development of the lens is useful model for several disease states and will 
be discussed more thoroughly later in this chapter. Observation of the epithelial 
layers around the eye as well as the developing lens (highlighted by the arrow) 
was found to be possible. To our knowledge, this ability to visualize the 
developing lens of a living zebrafish embryo with a small-molecule fluorophore 
has not been previously reported. In contrast to our observations of living 
embryos, in chemically fixed (dead) embryos, immunohistochemistry was 
previously used to observe developmental defects of the lens of these animals 
following knockdown of Hsp70.18 In another study, transgenic embryos have 
been used to image the vasculature of the lens of the developing embryo both in 
vivo19 and in dissected specimens.20 In addition to visualizing tissues of the eye, 
treatment with HR101 allowed individual mitochondria to be visualized in other 
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cell types including epithelial cells of the tail (Figure 4.2, panel E). Observation 
over time enabled visualization of mitochondrial fission and fusion events that are 
crucial for maintenance of mitochondrial health. HR101 appears to be the first 
small-molecule fluorophore to be identified that allows facile imaging of 




Figure 4.2. Panel A: Structures of the cationic mitochondrial fluorophores 
Rhodamine 123, MitoTracker Deep Red FM, HR101, and HRB. Panel B: 
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Confocal microscopy of HeLa cells treated with these compounds (100 nM, 
green fluorescence) and the nuclear stain Hoechst 33342 (1 µM, cyan 
fluorescence) for 30 min. The four cationic fluorophores can be observed to 
readily accumulate in mitochondria. Scale bar = 25 µm. Panel C: Treatment of 72 
hpf zebrafish embryos with HR101, HRB, MitoTracker DeepRed, and Rhodamine 
123 (1 µm, 1 h). Substantial fluorescence was only observed with HR101. Scale 
bar = 100 µm Panel D: Confocal Z-stack used to image HR101 in the developing 
eye of a living dechorinated 36 hpf zebrafish embryo. The arrow points to the 
developing lens. Scale bar = 50 µm. Z-stacks are colored by depth: blue to red 
(0–160 µm). Panel E: Confocal imaging of the tail of a living (36 hpf) zebrafish 
embryo treated with HR101 (100 nM, 8 h). Fusion and fission of mitochondria in 
vivo over time is observed (fission indicated by arrows). Scale bar = 25 µm. 
 
 
4.3 An Acid-Activated Fluorophore Reveals V-ATPase Activity 
 The pH of fluids of living animals is a fundamental physicochemical 
condition that is critically important for cellular homeostasis.21 Endosomes and 
lysosomes are two organelles that require low pH for proper function, and this 
acidity is maintained by pumping of protons into the vesicle lumen by the 
vacuolar ATPase (V-ATPase). When this process is blocked, failure to acidify 
endosomes can inhibit receptor trafficking in cell culture.22 Improper V-ATPase 
activity has been linked to a number of diseases including X-linked myopathy 
with excessive autophagy (XMEA)23 and osteoporosis.24 Experimentally, the pH 
of the endosome-lysosome system can be perturbed using small molecule 
inhibitors. Bafilomycin A1 is a macrolide antibiotic that specific inhibits the proton 
pumping activity of V-ATPase.25 Additionally, the anti-malaria drug chloroquine is 




Figure 4.3 Panel A: Structures of the acid-activated fluorophores KR54 and 
KR35. The equilibrium between the acid-activated, highly fluorescent form, and 
the ring-closed, non-fluorescent form is shown. Panel B: Fluorescence 
microscopy of zebrafish embryos (36 hpf) treated with KR54 and KR35 (10 µM, 1 
h). Only KR54 showed appreciable fluorescence staining. Scale bar = 2.5 mm. 
The brightfield images were contrast enhanced for clarity. Panel C: Confocal 
microscopy of a 36 hpf embryo treated with KR54 (10 µM, 30 min, green 
fluorescence) and the DNA stain SYBR green (10 µM, red fluorescence). KR54 
can be observed primarily around the yolk. Pretreatment of these animals with 
the V-ATPase inhibitor Bafilomycin A1 (200 nM, 30 min) reduces the acid-




The Peterson laboratory previously published the synthesis of acid-
activated fluorophores based on the structure of Rhodamine B (Figure 4.3, panel 
A).27 These fluorophores are highly fluorescent under acidic conditions, but revert 
to a non-fluorescent cyclized form under basic conditions. The pH range of the 
acid sensitivity was shown to be tunable by addition of electronegative fluorine 
atoms to either the ethylamine side chain or the bottom ring (i.e. KR54 pKa = 5.4, 
KR35 pKa = 3.5). These acid-activated fluorophores were previously used to 
probe dynamic changes in the acidity of the alimentary canal of the nematode C. 
elegans, illustrating the utility of these probes in observing dynamic processes in 
in vivo animal models. Because pH is a fundamental physical chemical condition 
that plays a prominent role in physiology, we examined the fluorescence of KR54 
and KR35 in treated zebrafish embryos. 
When dechorionated 36 hpf embryos were treated with KR54 (10 µM in 
PBS pH 7.4, 1 h), strong fluorescence was observed around the yolk of the 
embryo (Figure 4.3, panel B). This fluorescence is indicative of an acidic 
environment around this nutrient-rich tissue. However, when these embryos were 
treated with the structurally similar compound KR35, no significant fluorescent 
was observed (Figure 4.3, panel B), suggesting that the acidity around the yolk is 
likely to be in the range of pH 5–6. The results with KR54 are consistent with 
other reports28 that V-ATPase expressing cells surround the yolk of developing 
zebrafish. These acid-secreting cells are one type of ionocyte that are 
responsible for maintaining ion homeostasis in the embryonic zebrafish and are 
functionally homologous to the mammalian kidney.29 The removal of metabolic 
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acid by the V-ATPase cells is coupled with sodium ion import by other Na+-pump 
rich cells.28 Similar systems of ion balance through skin cells are known in other 
fish30 and amphibian species.31 Consistent with this model, embryos treated with 
V-ATPase inhibitor bafilomycin A1 showed decreased KR54 fluorescence (Figure 
4.3, panel C). KR54 appears to allow visualization of the pH-lowering effect of 
acid-secretion in this process of ion homeostasis. 
 
4.4 Conclusions 
 The zebrafish is an important vertebrate model organism that is 
particularly suited for large-scale, high-throughput studies. By screening this in 
vivo model against fluorophores that we previously reported, we found that the 
hydrophobic rhodamine HR101 is an effective probe of mitochondria of 
embryonic zebrafish. This probe appears to be the first small molecule that 
allows observation of the dynamics of individual mitochondria in this model 
organism in vivo. HR101 further provides a bright counterstain to observe 
developmental changes over time in specific tissues such as the eye in living 
embryos. Moreover, mitochondria of zebrafish are of substantial interest as 
models of human mitochondrial diseases.32-33 Unique models of 
neurodegenerative disorders like Parkinson’s disease34-36! and the first animal 
model of the developmental disease MADD (Multiple Acyl-CoA Dehydrogenase 
Deficiency)37 were developed in zebrafish. 
Previous efforts to visualize the zebrafish mitochondrial network have 
primarily used transgenic animals expressing mitochondrial-specific GFP, YFP, 
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or DsRed fusion proteins.16 Commercial MitoTracker dyes have been previously 
reported28 for use in living zebrafish embryos. However, these MitoTracker dyes 
were of limited utility since only a subset of cells was labeled. The superiority of 
HR101 in vivo was shown here by direct comparison with other fluorescent 
mitochondrial probes (Figure 4.2, panel C). As the first mitochondrial dye to 
efficiently penetrate into diverse tissues of living zebrafish embryos, HR101 could 
fill a critical role as a rapid-acting, potent, and bright fluorescent mitochondrial 
probe.  
By examining a series of acid-activated fluorophores, KR54 was shown to 
readily stain the exterior of the embryonic zebrafish yolk. This pattern of 
fluorescence suggested the presence of an acidic extracellular environment, and 
based on other reports28 was proposed to be a downstream effect of cells 
expressing V-ATPase.29 Consistent with this proposal, the fluorescence of KR54 
was inhibited by treatment with the V-ATPase inhibitor bafilomycin A1. V-ATPase 
activity has been shown to play important roles in zebrafish models of tissue 
regeneration,38 pigmentation,39 and development.40 As a novel probe in zebrafish 
biology, KR54 in zebrafish embryos could provide the basis for a unique and 
simple assay of V-ATPase activity in vivo. 
 
4.5 Future Directions and Applications 
The small molecules HR101 and KR54 represent examples of how 
fluorescent probes can be applied for novel studies of zebrafish embryos in vivo. 
In future studies, these and related compounds could be of significant interest for 
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high-throughput screening (HTS) and high content screening applications. 
Fluorophores such as KR54 and HR101 have potential for large-scale phenotypic 
screens looking directed at the discovery of inhibitors of V-ATPase activity, 
compounds that promote changes in mitochondria morphology, or agents that 
affect development. 
Phenotypic screens of small-molecule libraries have previously identified 
novel inhibitors of V-ATPase activity in yeast, and these types of inhibitors are of 
interest for treatment of a variety of diseases such as cancer and osteoporosis.41-
43 In future studies, treatment of zebrafish embryos with KR54 could serve as the 
first in vivo whole-animal model for screening V-ATPase activity. Since KR54 can 
be dosed directly into system water containing embryos, the assay could be 
straightforward to administer. By monitoring the fluorescence of KR54 around the 
yolk by microscopy, changes in intensity (increases or decreases) and 
distribution could be possible.  As shown in Figure 4.3C, the difference in KR54 
fluorescent signal between the DMSO control and the V-ATPase inhibition of 
bafilomycin A1 is quite substantial and this large difference could lend itself to 
automated analysis of V-ATPase activity.  
As the first small-molecule fluorophore known to accumulate in 
mitochondria of diverse peripheral issues, HR101 could provide a straightforward 
in vivo assay to identify compounds that perturb mitochondrial morphology. 
These types of compounds are of interest as probes and potential 
therapeutics.44-45 Previous cell-based chemical genetic screens have found 
several compounds that are cytoprotective through their ability to inhibit 
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mitochondrial fission46 or promote mitochondrial fusion,47 with potential 
applications as treatments for neurodegeneration. Similar assays in a vertebrate 
model using HR101 could detect alterations of mitochondrial morphology and 
concurrent changes in embryonic development. In order to further explore the 
potential of HR101 in zebrafish embryos, comparative toxicity studies between 
embryos and cell culture are planned. Combining observations of HR101 in living 
embryos with known genetic and chemical modulators of mitochondrial function 
will be critical in establishing the utility of these types of screens. As more small-
molecule fluorophores are investigated in this model organism, probes with 
unique photophysical and physicochemical properties have the potential to allow 
new discoveries in biology and medicine. 
 
4.6 Experimental  
4.6.1 Chemicals and molecular probes. Hydrophobic rhodamines (HR101 and 
HRB)17 and acid-activated fluorophores (KR54 and KR35)27 were prepared as 
previously described. Rhodamine 123, MitoTracker Deep Red FM, and 
SybrGreen were purchased from Invitrogen. Hoechst 33342 and Bafilomycin A1 
were purchased from Sigma. 
 
4.6.2 Animal Care. All work with zebrafish was approved by the KU IACUC. 
Wild-type adult zebrafish for breeding were obtained from Carolina Biological 
Supply Company or the Marine Biological Laboratory and housed in a Pentair 
Aquatic Habitats ZF0601 system. The system was set at 14 hours “lights-on,” 10 
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hours “lights-off.” Breeding experiments were done using a Pentair breeding tank 
and timed to daily “lights-on.” Zebrafish embryos were collected with a mesh 
strainer and thoroughly washed with E3 media. Dechorionation was done by 
dissecting microscopy with ultra-fine tweezers. Small-molecules were added in 
E3 medium or PBS (pH 7.4) as indicated. Compounds were diluted to final 
indicated concentrations from a 1000x DMSO stock. Embryo count and DMSO 
concentrations were normalized for all experiments to assure equal exposure. 
 
4.6.3 Cell Line. HeLa (CCL-2) cells were obtained from ATCC and cultured in a 
humidified CO2 (5%) incubator at 37 °C. Dulbecco’s Modified Eagle Medium 
(DMEM, Sigma D5796) was supplemented with FBS (10%, Sigma F0926), 
penicillin (100 units/L), and streptomycin (100 µg/L, Sigma P4333).  
 
4.6.4 Microscopy. Embryos were imaged in 8-well cover glass slides (Idibi µ-
Slide) with a Leica SPE2 confocal laser scanning microscope fitted with either a 
10x, 20x, 40x (oil emersion), 40x LWD (long working distance), or 63x objective. 
HR101, HRB, KR54, KR35 were excited using a 532 nm laser and photons were 
collected from 550 nm – 650 nm. MitoTracker DeepRed FM (MTDR) was excited 
using a 635 nm laser and photons were collected from 650 nm – 750 nm. SYBR 
Green was excited with a 488 nm laser and photons were collected from 500 nm 
– 520 nm. Hoechst 3342 was excited with a 405 nm laser and photons were 
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Ethylene glycol-linked Dimers of Cholesterol as Stabilizers of Liposomes 
 
5.1 Introduction 
Lipid vesicles (liposomes) have been widely investigated in drug-delivery 
systems.1-2 As of early 2015, a number of drugs have been approved as 
liposomal formulations including doxorubicin,3-4 vincristine,5 and morphine.6 In 
total, 11 different marketed agents use liposomes, and a number of similar 
agents are currently in clinical trials.2 Liposomes can benefit delivery by changing 
the pharmacokinetic parameters of an agent, including solubility, half-life, or 
selective distribution into tissues.7 
Liposomes for drug delivery include phospholipids such as 
distearoylphosphotidylcholine (DSPC). The choice of these phospholipids can 
greatly impact the function of a liposome by altering properties of membrane 
fluidity, charge, and stability.2  Cholesterol (11) is also commonly used in 
liposome formation as it favorably alters the biophysical properties of the 
liposome. This sterol (11) is a critical component of mammalian cell membrane 
and accounts for approximately 30 mol% of the lipids of mammalian plasma 
membranes.8 When included in liposomes at approximately 30 mol %, 
cholesterol eliminates the thermotropic phase transition of the phospholipid 
component9 and limits membrane permeability.10 However, cholesterol 
incorporated into the liposome bilayer can transfer to other biological bilayers or 
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macromolecules, which can induce premature leakage of encapsulated 
substances.7, 11 
Synthetic cholesterol-modified phospholipids have previously been 
reported to limit extraction of cholesterol from liposomes in vivo.12-13 To this end, 
Szoka and co-workers prepared cholesterol-modified phospholipid dimers that 
exhibit higher membrane stability than free cholesterol in biological systems.13  
The most promising compound, DChemsPC (12), contains two cholesteryl units 
at both the sn-1 and sn-2 positions of phosphatidylcholine connected through 
succinyl diester linkages. Liposomes that incorporate 12 exhibit favorable 
properties compared with unmodified cholesterol including eliminating cholesterol 
exchange, reducing membrane leakage, and efficient delivery of doxorubicin in 
vivo comparable to Doxil.13 
While the protective affects of 12 were promising, several factors could 
potentially limit the large scale utility of this agent. Although 12 is commercially 
available (Avanti), it is expensive at $1,650 per gram. Additionally, the published 
synthesis of 12 uses a glycerolic phosphocholine starting material of unspecified 
stereochemistry, leaving the possibility of a diastereomeric mixture of final 
products.13 The cholesterol esters and phosphoglycerol esters in this compound 
also potentially leave liposomes susceptible to endogenous lipases.14 With these 
issues in mind, we set out to design and test structurally simplified cholesterol 
dimers that could retain and potentially improve upon the liposomal stabilization 
of 12, but are synthetically more practical for larger scale formulation.  
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Figure 5.1. Structures of cholesterol (11), the previously reported cholesterol-
modified phospholipid DChemsPC (12), and the novel cholesterol dimers 13–19 
bearing systematic modifications in linker type and length.  
 
5.2 Synthesis of Novel Ethylene Glycol-Linked Cholesterol Dimers 
We hypothesized that the phosphocholine triglyceride could be 
functionally replaced with polar ethylene glycol linkers of various lengths. This 
simple modification might generate dimers that are potentially more synthetically 
accessible with favorable membrane protective effects similar to dimer 12. To 
test this hypothesis, novel cholesterol dimers 13-19 were designed that 
systematically varied the number of ethylene glycol units as well as the functional 
group for attachment of the steroid to the linker (Figure 5.1). The synthesis of 
these novel dimers is outlined in Figure 5.2. The starting material 20a is 
commercially available, and 20b-c and 21a-c were prepared from inexpensive 
commercial alcohols. Amide 13 was prepared from the intermediate acyl chloride 
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and 3β-cholesterylamine.15 Esters 14-16 were prepared using DCC coupling of 
free cholesterol at slightly elevated temperatures. Carbamates 17-19 were 
prepared from condensation of aminoethylene glycols with cholesterol 
chloroformate. Although these dimers were made in low to moderate yields (28 -
65%), the products could be readily purified by normal phase silica 
chromatography, and the starting materials were generally inexpensive, making 
them highly accessible for further studies. 
 
 
Figure 5.2. Synthesis of the novel cholesterol dimers 13-19. 
 
5.3 Studies of Liposomal Stability 
 To evaluate the stability of liposomes prepared with the new cholesterol 
dimers, we collaborated with the laboratory of Prof. Rodney Ho (U. Washington). 
The Ho laboratory prepared liposomes using 11-19 as potential stabilizing 
agents. It was found that all cholesterol compounds except 13 formed stable 
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liposomes of similar size (Figure 5.3, panel A). Amide 13 was unable to stabilize 
liposomes, possibly due to limited incorporation in the bilayer resulting from the 
higher rigidity of the amide linkage in the dimer. 
 To examine the effects of the new cholesterol dimers on liposomes, our 
collaborators examined the effect of binding of total serum proteins to liposomes. 
As negative and positive controls, liposomes were prepared with either 11 (free 
cholesterol) or the previously reported dimer 12 (Figure 5.3, panel B). To test 
liposome stability under approximate in vivo conditions, liposome samples were 
incubated in 100% monkey serum (macaque) for either 1 or 24 hours and 
stability was measured by monitoring leakage of the encapsulated fluorophore 
calcein. After 1 h, all dimers except for 17 showed improved liposome stability 
compared to free cholesterol similar to that seen with 12. After 24 h, all samples 
showed increase leakage, but the dimers 14–16, 18, & 19 showed stability equal 





Figure 5.3. Panel A: Average sizes of liposomes containing 45 mol% cholesterol 
or 22.5 mol% of the indicated dimer (equivalent for total cholesterol) and 55% 
DSPC. Compound 13 failed to form stable liposomes in DSPC. Panel B: Protein 
binding to liposomes formulated with each cholesterol agent. Values are 
normalized to protein binding of liposomes containing free cholesterol. Panel C: 
Stability of liposomes formulated with each cholesterol agent in 100% primate 
serum for 1 h. Stability was measured by release of encapsulated calcein. Panel 
D: Stability of liposomes formulated with each cholesterol agent in 100% primate 
serum for 24h. Stability was measured by release of encapsulated calein. Data 








5.4 Analysis of Liposome Composition by Mass Spectrometry 
 To quantify the components of the liposomes prepared by our 
collaborators, mass spectrometry was used to assay the phospholipid 
component DSPC as well as its hydrolysis product LysoPC (18:0 lysoPC; 1-
stearoyl-2-hydroxy-sn-glycero-3-phosphocholine, Figure 5.4, panel A). Using 
commercial lipids, a standard curve was developed to allow for direct 
quantification of each phosphocholine compound from the total integrated ion 
count (Figure 5.4, panel B). At low concentrations, the ion count is linear, which 
allows simple conversion from ion count back to physical quantity in test 
samples. Since endogenous lipases have the potential to degrade the prepared 
liposomes in vivo, a mass spectrometry-based lipase assay was developed. 
Using commercial DSPC, increasing amounts of porcine pancreatic lipase (PPL, 
0 – 1250 U/mL) produced increasing amount of the lysoPC product that could be 
quantified using the standard curve (Figure 5.4, panel C). Interestingly, in 
liposomes prepared with 11, 12, 16, or 19 treated with the same PPL reaction 
conditions, no appreciable change in lysoPC product levels were observed 
(Figure 5.4, panel D). These initial results suggest the phospholipids in the 
prepared liposome samples are less susceptible to hydrolysis by lipases such as 
PPL. However, further investigation into other lipases or different conditions is 
warranted. The mass spec analytical technique developed here should serve as 
a fast and reliable assay for future investigations of lipase activity.  
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Figure 5.4. Panel A: The standard curve comparing injected samples (ng/µL) 
verses ion count (ESI+). Panel B: Optimization of lipase concentration (U/mL) in 
the hydrolysis reaction of DSPC (10 µM). Panel C: Changes in analyte levels of 
liposomes (10 mM) treated with lipase (500 U/mL, 1 h) normalized to untreated 
liposome samples. No significant changes in DSPC levels were observed. *The 
apparent decrease in lysoPC for liposome 19 is due to high starting levels of 
lysoPC in the sample. Panel D: Structures of the analytes DSPC and the 
hydrolysis product lysoPC detected by mass spectrometry.  
 
5.5 Conclusions 
 This proof-of-concept study suggests that cholesterol dimers bearing 
linkers containing ethylene glycol units can serve as efficient stabilizers of 
liposome membranes similar to more complex previously reported cholesterol 
dimers.12-13 Through systematic variation of the number of ethylene glycol units 
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as well as the functional group of the linker, it was shown that longer chain 
dimers such as ester 16 and carbamate 19 can significantly decrease protein 
binding and membrane leakage compared to that of free cholesterol and may be 
superior in some assays to the known compound 12. Interestingly, liposomes of 
17 showed decrease stability and increased leakage compared with free 
cholesterol, suggesting that the shorter carbamate linkage prevented stable 
incorporation of this dimer into the lipid bilayer.  
The beneficial effects of the ethylene glycol linkages observed in this 
study are fully consistent with that seen in other pegylated liposomes,16 
nanoparticles,17 protein therapies.18-19 Pegylation has been shown to increase 
bioavailability and decrease in vivo degradation by acting to shield the 
therapeutic agent from biological systems. In fact, the marketed liposomal 
doxorubicin contains PEG units to increase its half-life in circulation.4 These 
results suggest that more detailed investigations comparing 12 with the novel 
dimers are warranted for potential drug delivery applications.   
 
5.6 Experimental Methods 
5.6.1 General. 1H (500 MHz) and 13C (125 MHz) NMR spectra were acquired on 
a Bruker Avance AC-III 500 instrument. Chemical shifts were reported in 
reference to CDCl3 (7.26 for 1H and 77.16 for 13C). Coupling constants are 
reported in hertz and are reported as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, dt = double 
of triplets, m = multiplet, b = broad), coupling constant, and integration. High-
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resolution mass spectrometry was done on a Micromass LCT Premier 
instrument. Melting points were obtained on a Thomas-Hoover capillary melting 
point apparatus and are uncorrected. Thin-layer chromatography (TLC) used 
EMD aluminum-backed silica plates (0.20 mm, 60 F-254) and compounds were 
visualized with ceric sulfate/molybdic acid. Flash chromatography used ICN silica 
gel (200-400 mesh) and was carried out using a gradient of either methanol (0 – 
4%) in dichloromethane or ethyl acetate (0 – 30%) in hexanes. All reactions were 
carried out using oven-dried glassware. Dichloromethane and dimethylformamide 
used in reactions was purified via filtration through two columns of activated 
basic alumina under an atmosphere of Ar using a Glass Contour solvent 
purification system. Commercial ethylene glycol derivatives were dried under 
high vacuum to remove excess water prior to use. All other reagents were 
purchased from Sigma or Fisher and used as provided. 1,11-diamino-3,6,9-
trioxaundecane,20 1,14-diamino-3,6,9,12-tetraoxatetradecane,21 1,17-diamino-3,
6,9,12,15-pentaheptadecane,22 3,6,9,12- tetraoxatetradecanedioic acid,23 3,6,9,
12,15-pentaheptadecanedioic acid,23 and 3β-cholesterylamine15 were 
synthesized as previously reported. 
 
5.6.2 Liposome Preparation and in vitro Stability Assays. The preparation of 
liposomes and the stability assays shown for Figure 5.3 were conducted by the 
lab of Rodney Ho at the University of Washington. They are described here for 
reference. Stocks of phospholipids, cholesterol, and the dimers 12-19 were 
prepared in chloroform:methanol (2:1). Liposomes were prepared by adding 
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appropriate amounts of the stock solutions to a glass tube at a final molar ratio of 
55:45 DPSC:cholesterol (dimers were calculated as 2 mol equivalents of free 
cholesterol). The organic solvent was removed with a stream of nitrogen and the 
lipids were rehydrated (PBS at 60 ˚C with sonication). Final concentrations of the 
liposome solutions, based on the amount of lipid added, were 10 mM. Liposome 
sizes were analyzed on a Nicomp 380 PSS by light scattering according to 
manufacturer guidelines. Serum protein binding was determined by incubating 
liposome samples (100 µL, 10 mM) with monkey serum (100 µL, macaque, 
harvested at the University of Washington, 37 ˚C, 24 h). The liposome-protein 
complexes were eluted through an Agarose M50 column (PBS, pH 7.4). Protein 
concentrations were determined with a standard BCA assay (Sigma) according 
to manufacturer guidelines. Liposomal stability assays in monkey (macque) 
serum were conducted with liposomes formulated as above but with 
encapsulated calcein (50 mM). Liposome samples (200 µL) were treated with 
PBS, FBS (30% in PBS), or macaque serum (1.8 mL, 24 h at room temperature).  
Release of calcein was measured on a standard plate reader and normalized 
between PBS negative controls and samples lysed with 5 µL of a 10% Triton X-
100 solution. 
  
5.6.3 Mass Spectrometry Methods. DSPC and 18:0 LysoPC were obtained 
from Avanti. Porcine pancreatic lipase (PPL) was from Lee Bioscience. PPL 
stocks were prepared in TBS (50 mM TrisHCl, 150 mM NaCl, pH 8.0, CaCl2 55 
mM, 1% BSA). Lipase assays were carried out with 50 µL of liposome or pure 
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DSPC + 5 µL lipase (5500 U/mL stock) for 1 h at 37 ˚C.  Stocks (10 mM) of 
phospholipids in chloroform:methanol (2:1) were prepared and serial diluted with 
chloroform:methanol (2:1) + 0.01% formic acid for the standard curve. Mass spec 
analysis was performed on a Waters MicromassZQ electrospray instrument fitted 
with a 10 µL injection loop. The standard curves were obtained with 10 µL 
injections and total ion counts integrated over 25 seconds from the 
chromatograph. Linear least squares fitting used GraphPad Prism 6.0.  Lipase 
concentrations in the hydrolysis reaction was optimized using 0 -1250 U/mL PPL. 
Suspensions of pure DSPC were prepared by evaporating CHCl3 solution in a 
glass vial with a flow of N2, PBS pH 7.4 was added for a final lipid concentration 
of 10 mM and the solution was sonicated for 30 min in a standard water bath to 
give a cloudy suspension of liposomes. 
 
5.6.4 Chemical Synthesis and Characterization 
 
Amide-2-glycol dimer (13). 3,6,9-Trioxaundecanedioic acid (0.2 g, 0.9 mmol) 
was cooled to 4 °C and neat thionyl chloride (0.26 mL, 3.6 mmol) was added 
dropwise.  The mixture was warmed to room temperature and stirred for 1 h. 
Excess thionyl chloride was removed under reduced pressure.  The crude 
intermediate was treated with 3β-cholesterylamine (0.76 g, 1.98 mmol) in a 
solution of CH2Cl2 (3 mL). Triethylamine (0.38 mL, 2.7mmol) was then added and 
reaction was stirred for 16 h. The solvents were removed under reduced 
pressure and the reaction was purified by column chromatography to produce 
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compound 13 as a white solid (450 mg, 52%). 1H NMR (500 MHz, Chloroform-d) 
δ 6.65 (d, J = 8.5 Hz, 2H), 5.35 (dt, J = 5.6, 2.0 Hz, 2H), 3.97 (s, 4H), 3.80 – 3.61 
(m, 10H), 2.37 – 0.78 (m, 80H), 0.67 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 
168.63, 140.06, 122.11, 70.71, 70.46, 70.18, 56.66, 56.11, 50.06, 49.08, 42.29, 
39.71, 39.51, 39.21, 37.85, 36.55, 36.18, 35.81, 31.84, 29.09, 28.24, 28.02, 
24.28, 23.83, 22.84, 22.58, 20.98, 19.40, 18.72, 11.87.HRMS (ESI) m/z 
957.8067 (M+H C62H105N2O5+ requires 957.8023). mp 160-164 ºC. 
 
Ester-2-glycol dimer (14). To a stirred solution of 3,6,9-Trioxaundecanedioic 
acid (0.1 g, 0.45 mmol) in THF (3 mL) at 4 °C was sequentially added DCC (232 
mg, 1.125 mmol), cholesterol (382 mg, 0.99 mmol), and 4-dimethylaminopyridine 
(5.5 mg, 0.045 mmol). The mixture was warmed to 60 °C and stirred overnight 
(16 h). The solution was cooled to room temperature and filtered. The filtrate was 
concentrated, re-suspended in CH2Cl2, and filtered again. The product was 
purified by silica column chromatography to give pure 14 as a white solid (122 
mg, 28%). 1H NMR (500 MHz, Chloroform-d) δ 5.37 (m, 2H), 4.76 – 4.63 (m, 2H), 
4.12 (s, 4H), 3.80 – 3.64 (m, 10H), 2.40 – 0.81 (m, 80H), 0.67 (s, 6H). 13C NMR 
(126 MHz, CDCl3) δ 169.90, 139.40, 122.89, 74.60, 70.84, 70.64, 68.86, 56.67, 
56.12, 49.99, 42.31, 39.71, 39.52, 38.07, 36.94, 36.57, 36.18, 35.81, 31.90, 
31.84, 29.72, 28.24, 28.03, 27.75, 24.29, 23.84, 22.84, 22.58, 21.03, 19.32, 
18.72, 11.87. HRMS (ESI) m/z 981.7549 (M + Na, C62H102O7Na+ requires 
981.7523). mp 129-131 ºC. 
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Ester-3-glycol dimer (15). The synthesis was as described for 14 but using 
3,6,9,12- tetraoxatetradecanedioic acid (0.7511 mmol) as the starting material to 
give 15 as a white solid (279.7 mg, 37%). 1H NMR (500 MHz, Chloroform-d) δ 
5.30 (m, 2H), 4.64 (m, 2H), 4.06 (s, 4H), 3.69 – 3.58 (m, 12H), 2.27– 0.77 (m, 
80H), 0.61 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 169.91, 139.39, 122.90, 74.59, 
70.84, 70.64, 70.59, 68.84, 56.67, 56.12, 49.99, 42.31, 39.71, 39.52, 38.07, 
36.93, 36.57, 36.18, 35.81, 33.97, 31.90, 31.84, 28.24, 28.03, 27.75, 25.62, 
24.96, 24.29, 23.84, 22.85, 22.58, 21.03, 19.32, 18.72, 11.87. HRMS (ESI) m/z 
1025.8036 (M+Na C64H106O8Na+ requires 1025.7785). mp 111 ºC. 
 
 
Ester-5-glycol dimer (16). The synthesis was as described for 14 but using 3,6,
9,12,15-pentaheptadecanedioic acid (0.741 mmol) as the starting material to give 
16 as a white solid (261.6 mg, 34%). 1H NMR (500 MHz, Chloroform-d) δ 5.40 (d, 
J = 3.7 Hz, 2H), 4.71 (ddt, J = 16.2, 8.1, 4.2 Hz, 2H), 4.14 (s, 4H), 3.78 – 3.64 (m, 
24H), 2.35 (m, 80H), 0.69 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 169.91, 139.39, 
122.89, 74.58, 70.85, 70.62, 70.60, 70.59, 68.84, 56.67, 56.12, 49.98, 42.31, 
39.71, 39.52, 38.07, 36.93, 36.57, 36.18, 35.81, 31.90, 31.84, 28.24, 28.03, 
27.75, 24.29, 23.84, 22.85, 22.58, 21.03, 19.32, 18.72, 11.87. HRMS (ESI) m/z 
1069.8356 (M+Na C66H110O9Na+ requires 1069.8048). mp 104ºC. 
 
Carbamate-2-glycol dimer (17). To a solution of 1,11-diamino-3,6,9-
trioxaundecane (100 mg, 0.52 mmol) and cholesterol chloroformate (514 mg, 
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1.14 mmol) in dry dichloromethane (2 mL) at room temperature, triethylamine 
(283 µL, 2.08 mmol) was added dropwise. The resulting solution was stirred for 2 
h. The reaction was diluted with dichloromethane (8 mL) and water was added 
(30 mL). The reaction was extracted with CH2Cl2 (2 x 15 mL) and the pooled 
organic layers were dried over sodium sulfate, filtered, and the solvent was 
removed. The crude reaction was purified by silica chromatography to give 17 as 
a white solid (217 mg, 41%). 1H NMR (500 MHz, Chloroform-d) δ 5.36 (dt, J = 
5.6, 2.1 Hz, 2H), 5.20 (s, 2H), 4.58 – 4.37 (m, 2H), 3.69 – 3.47 (m, 12H), 3.36 (q, 
J = 5.3 Hz, 4H), 2.45 – 0.76 (m, 80H), 0.67 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 
156.22, 139.84, 122.47, 74.30, 70.51, 70.25, 70.19, 56.68, 56.12, 49.99, 42.31, 
40.69, 39.73, 39.52, 38.60, 37.00, 36.56, 36.18, 35.81, 31.91, 31.87, 28.25, 
28.20, 28.02, 24.29, 23.84, 22.84, 22.58, 21.05, 19.36, 18.72, 11.87. HRMS 
(ESI) m/z 1017.8250 (M+H C64H109N2O7+ requires 1017.8235). mp 137-141 
ºC. 
 
Carbamate-3-glycol dimer (18). The synthesis was as described for 17 but 
using 1,14-diamino-3,6,9,12-tetraoxatetradecane (0.635 mmol) as the starting 
material to give 18 as a white solid (436 mg, 65%). 1H NMR (500 MHz, 
Chloroform-d) δ 5.47 – 5.21 (m, 4H), 4.60 – 4.42 (m, 2H), 3.77 – 3.57 (m, 12H), 
3.57 (t, J = 5.1 Hz, 4H), 3.38 (q, J = 5.2 Hz, 4H), 2.46 – 0.81 (m, 80H), 0.69 (s, 
6H). 13C NMR (126 MHz, CDCl3) δ 156.28, 139.87, 122.45, 74.25, 70.58, 70.51, 
70.27, 70.24, 56.68, 56.12, 49.99, 42.31, 40.70, 39.73, 39.52, 38.61, 37.00, 
36.56, 36.18, 35.81, 31.91, 31.87, 28.25, 28.20, 28.02, 24.30, 23.84, 22.84, 
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22.58, 21.05, 19.36, 18.72, 11.87. HRMS (ESI) m/z 1061.8538 (M+H 
C66H113N2O8+ requires 1061.8497). mp 139-141 ºC. 
 
Carbamate-4-glycol dimer (19). The synthesis was as described for 17 but 
using 1,16-diamino-3,6,9,12,15-pentaoxatetradecane (1.785 mmol) as the 
starting material to give 19 as a white, vicious solid (965 mg, 49%). 1H NMR (500 
MHz, Chloroform-d) δ 5.43 – 5.35 (m, 2H), 5.27 (t, J = 5.7 Hz, 2H), 4.50 (ddd, J = 
16.2, 10.0, 3.7 Hz, 2H), 3.72 – 3.60 (m, 16H), 3.56 (t, J = 5.1 Hz, 4H), 3.37 (q, J 
= 5.3 Hz, 4H), 2.41 – 0.85 (m, 80H), 0.69 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 
156.24, 139.85, 122.46, 74.23, 70.61, 70.58, 70.52, 70.25, 70.17, 56.67, 56.11, 
49.98, 42.30, 40.69, 39.72, 39.51, 38.61, 37.00, 36.55, 36.18, 35.81, 31.90, 
31.86, 28.25, 28.20, 28.02, 24.29, 23.84, 22.85, 22.58, 21.04, 19.36, 18.72, 
11.87. HRMS (ESI) m/z 1127.8960 (M+Na C68H116N2O9Na+ requires 
1127.8579). mp 104 ºC. 
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Figure 6.10. 13C NMR (126 MHz, CDCl3) spectrum of 7. The inset shows an 
expansion to illustrate the broad resonance of the ipso carbon of the furan linked 
















































Figure 6.14. 13C NMR (126 MHz, CDCl3/CD3OD, 9:1) spectrum of 10.  
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 Figure 6.15. 1H NMR of compound 13 in CDCl3. 
Figure 6.16. 13C NMR of compound 13 in CDCl3. 
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Figure 6.17 1H NMR of compound 14 in CDCl3. 
 
Figure 6.18 13C NMR of compound 14 in CDCl3. 
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Figure 6.19 1H NMR of compound 15 in CDCl3. 
 




Figure 6.21 1H NMR of compound 16 in CDCl3. 
 
Figure 6.22 13C NMR of compound 16 in CDCl3. 
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Figure 6.23 1H NMR of compound 17 in CDCl3. 
 
Figure 6.24 13C NMR of compound 17 in CDCl3. 
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Figure 6.25 1H NMR of compound 18 in CDCl3. 
 
Figure 6.26 13C NMR of compound 18 in CDCl3. 
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Figure 6.27 1H NMR of compound 19 in CDCl3. 
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pEGFP-N1 EGFP n/a pEGFP-N1 Mammalian Clonetech Clonetech  
#6085-1 
mCerulean-N1 Cerulean n/a pEGFP-N1 Mammalian Addgene Addgene 
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